



(11) **EP 1 033 979 B2**

(12) **NEW EUROPEAN PATENT SPECIFICATION**
After opposition procedure

- (45) Date of publication and mention of the opposition decision: **24.02.2010 Bulletin 2010/08**
- (45) Mention of the grant of the patent: **09.08.2006 Bulletin 2006/32**
- (21) Application number: **98956735.9**
- (22) Date of filing: **01.12.1998**
- (51) Int Cl.:
A61K 31/465^(2006.01) A61K 31/37^(2006.01)
A61K 31/137^(2006.01) A61P 35/00^(2006.01)
A61P 43/00^(2006.01)
- (86) International application number:
PCT/CA1998/001093
- (87) International publication number:
WO 1999/027919 (10.06.1999 Gazette 1999/23)

(54) **COMBINATION OF CYP2A6 ENZYME INHIBITORS AND NICOTINE AND THEIR THERAPEUTIC USE**

WIRKSTOFFKOMBINATION AUS CYP2A6 ENZYME INHIBITOREN UND NIKOTINE UND IHRE THERAPEUTISCHE ANWENDUNG

COMBINAISONS D'INHIBITEURS DES ENZYMES CYP2A6 ET DE NICOTINE ET LEUR UTILISATION THERAPEUTIQUE

- (84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
- (30) Priority: **01.12.1997 US 67020 P**
01.12.1997 US 67021 P
08.05.1998 US 84847 P
06.11.1998 US 107392 P
- (43) Date of publication of application:
13.09.2000 Bulletin 2000/37
- (73) Proprietor: **Nicogen Inc.**
Toronto ON M5V 2T3 (CA)
- (72) Inventors:
• **SELLERS, Edward, M.**
Toronto, Ontario M6S 1B2 (CA)
• **TYNDALE, Rachel, F.**
Toronto, Ontario M5S 2L7 (CA)
- (74) Representative: **Bösl, Raphael Konrad**
Isenbruck Bösl Hörschler Wichmann LLP
Prinzregentenstrasse 68
81675 München (DE)
- (56) References cited:
WO-A-95/34679 WO-A2-98/03171
- **M. NAKAJIMA ET AL.:** "Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes." **J. PHARMACOL. EXP. THERAP.**, vol. 277, no. 2, 1996, pages 1010-1015, XP002050001
 - **M. NAKAJIMA ET AL.:** "Role of human cytochrome P4502A6 in C-oxidation of nicotine." **DRUG METABOL. DISPOS.**, vol. 24, no. 11, 1996, pages 1212-1217, XP002050002
 - **A. TSUJIMOTO ET AL.:** "Potent inhibitory action of pilocarpine on hepatic drug metabolism." **JPN. J. PHARMACOL.**, vol. 22, no. 5, 1972, pages 736-739, XP002050003
 - **A. TSUJIMOTO ET AL.:** "A study of the nature of pilocarpine inhibition of hepatic drug-metabolizing enzymes." **BIOCHEM. PHARMACOL.**, vol. 26, no. 21, 1977, pages 2072-2074, XP002050004
 - **H. FOTH ET AL.:** "Nicotine metabolism in isolated perfused lung and liver of phenobarbital- and benzoflavone-treated rats." **ARCH. TOXICOL.**, vol. 65, no. 1, 1991, pages 68-72, XP002050005
 - **G.A. KYEREMATEN ET AL.:** "Metabolism of nicotine by hepatocytes." **BIOCHEM. PHARMACOL.**, vol. 40, no. 8, 1990, pages 1747-1756, XP002050006
 - **H. YAMAZAKI ET AL.:** "Cytochrome P450 sE1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes." **CARCINOGENESIS**, vol. 13, no. 10, 1992, pages 1789-1794, XP002050007
 - **J. INVEST. MED. SUPPL** vol. 44, no. 1, 1996,
 - **SCRIP** vol. 2192, no. 23, December 1996,
 - **SCRIP** vol. 2234, no. 18, May 1997,
 - **SCRIP** vol. 2249, no. 16, July 1997,
 - **Selegiline Pilot Study of Nicogen**

EP 1 033 979 B2

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description**FIELD OF THE INVENTION**

5 **[0001]** The invention relates to regulating nicotine metabolism in an individual; and enhancing nicotine replacement therapies.

REVIEW OF THE ART

10 **[0002]** Nicotine is one of the most widely used psychoactive drugs in the world. The World Health Organization reports that there are currently in excess of 1 billion smokers worldwide, or roughly one-third of the global population aged 15 years and older. It is well established that smoking is associated with a higher incidence of many diseases, including various types of cancers, respiratory diseases, cardiovascular diseases, gastrointestinal disorders, as well as many other medical complications (Lee et al., Arch. Intern. Med., "Cigarette smoking, nicotine addiction, and its pharmacologic treatment," 153(1): 34-48 (1993)).

15 **[0003]** Nicotine is the primary compound present in tobacco that is responsible for establishing and maintaining tobacco dependence (Henningfield et al., J. Pharmacol. Exp. Ther., "Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine," 234(1): 1-12 (1985)). Specifically, it has been established in the art that dependent smokers adjust their smoking behaviour to maintain central nicotine levels (McMorrow MJ, et al., "Nicotine's role in smoking: an analysis of nicotine regulation," Psychological Bulletin, 93(2):302-27 (1983); Russell MSH, "Nicotine intake and its regulation by smokers. Tobacco smoking and nicotine," Advances, in behavioural biology, Martin WR, et al., New York, Plenum Press, 31:25-50 (1987)). It has been further established that: (i) smoking increases if nicotine content in cigarettes is decreased (Benowitz NL, "Drug Therapy. Pharmacologic Aspects of Cigarette Smoking and Nicotine Ad-
20 diction," New Engl. J. Med., 319(20): 1318-30 (1988)), (ii) smoking increases if nicotine excretion is increased by urine acidification (Benowitz NL, "The Use of Biologic Fluid Samples in Assessing Tobacco Smoke Consumption," NIDA Res. Monogr., 48:6-26 (1983)), and (iii) smoking decreases with administration of nicotine via concurrent I.V. or patch nicotine (Benowitz. NL et al., "Nicotine Metabolic Profile in Man: Comparison of Cigarette Smoking and Transdermal Nicotine", J. Pharmacol. Exp. Ther., 268(1):296-303 (1994); and Benowitz, NL et al., "Intravenous Nicotine Replacement Sup-
25 presses Nicotine Intake From Cigarette Smoking", J. Pharmacol. Exp. Ther., 254(3):1000-5 (1990)).

30 **[0004]** In light of the key role of nicotine in producing tobacco dependence and regulating smoking behaviour, it is important to understand the pattern of nicotine metabolism and the sources of variation of this metabolism in humans.

[0005] In humans, 60-85 % of nicotine is metabolized to the inactive metabolite cotinine (Benowitz, *et al.* 1994). The cytochrome P450 (CYP) system has been implicated in the metabolism of nicotine. Evidence for CYP involvement in nicotine metabolism has come from rat liver studies in which reconstituted purified CYPs, and specific antibodies were
35 shown to inhibit nicotine metabolism. In particular, rat studies have shown that phenobarbital inducible CYPs (i.e., the CYPs ; -2B1, -2B2, -2C6, and -3A2) are involved in nicotine metabolism. Of 12 human CYPs forms tested, CYP2B6 showed the highest nicotine oxidase activity while CYP2E1 and CYP2C9 showed intermediate levels (Flammang et al., "Nicotine metabolism by cDNA-expressed human cytochrome P-450s," Biochem. Arch., 8:1-8 (1992)). cDNA studies have implicated CYP2B6, CYP2C9, CYP2D6 and CYP2E1 and have provided a possible role for CYP2A6 in nicotine
40 metabolism in isolated expression systems (Flammang *et al.*, 1992; McCracken et al., "Cotinine formation by cDNA-expressed human cytochromes P450," Med. Sci.Res., 20:877-878 (1992)).

[0006] In copending International patent application S. N. PCT/CA97/00506 (filed July 17, 1997), the contents of which are hereby incorporated by reference, the present inventors teach that the genetically polymorphic CYP2A6 enzyme is the major enzyme responsible for this metabolic conversion. In human populations there is considerable interindividual
45 variability in hepatic CYP2A6 function measured *in vivo* and *in vitro* (Yamano S, et al., "The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes," Biochemistry, 29:1322-1329 (1990); Cholerton S, et al., "Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine," Journal of Chromatography, 575(2):325-30 (1992); Rautio A, et al., "Interindividual variability of coumarin 7-hydroxylation in healthy volunteers," Pharmacogenetics 2(5):227-33
50 (1992); and Iscan et al., "Interindividual variability of coumarin 7-hydroxylation in a Turkish population," Eur. J. Clin. Pharmacol. 47(4):315-318 (1994)).

[0007] WO 95/34679 describes that coumarin sometimes associated to cimetidine is used to treat neoplastic diseases. RU 2066998 describes a antiviral comprising cichorium intybus. WO 97/13489 describes an antidepressant comprising hypercium. Nakagina et al (J. Pharnzacol. Exp. Ther. 272:1010-1015, 1996) discloses that the pharmacological effects
55 of tobacco (i.e. of smoking) are due to nicotine and that the metabolic conversion of nicotine to continue and trans-3'-hydroxycotinine by action of the enzyme CYP2A6 is inhibited by coumarin. Yamazaki et al (Carcinogenesis, 13(10), 1789-1794, 1992) discloses that CYP2A6 catalyses the transformation of tobacco-smoke-related nitrosamines to genotoxic products.

5 [0008] Tobacco products are vehicles for the delivery of nicotine to the bloodstream which quickly carries nicotine to the brain and other organs. Nicotine produces many physiological and behavioural effects, including alteration of brain chemistry and function, which leads to an individual's dependence on nicotine. Dependent smokers adjust their smoking behaviour to regulate nicotine in the brain and body. Evidence includes increased smoking if nicotine content in cigarettes is decreased (Benowitz 1988), increased smoking if nicotine excretion is increased by urine acidification (Benowitz 1983), and decreased smoking with concurrent I. V. or patch nicotine (Benowitz, *et al.* 1994; Benowitz NL, *et al.* 1990).

10 [0009] While the art has made strides in gaining an understanding of the pattern of nicotine metabolism and the sources of variation of this metabolism in humans, there is still room for improvement. One area which has received little or no attention is in the diagnosis of risks for smoking and tobacco-related cancers, for example in non-smokers of relatively young age. In particular, it would be desirable to have a means by which it would be possible to readily identify individuals who: (i) have a decreased risk of becoming smokers, (ii) smoke less if they become dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased enzyme-mediated activation of tobacco smoke procarcinogens.

15 [0010] Other than nicotine dependence as a result of tobacco use, nicotine itself is not considered hazardous, namely it is not considered to be a causative agent in cancer and heart and lung disease. It is the other products which are found in tobacco products which are considered to be harmful, including combustion products such as carbon monoxide, gases and tar.

20 [0011] Nicotine replacement therapies (also referred to throughout this disclosure as "NRT's") are used to deliver nicotine to individuals in an attempt to assist an individual in abstaining from tobacco products. Recently, in a United Nations Conference on Trade and Development, entitled "Roundtable on Social and Economic Aspects of Reduction of Tobacco Smoking by Use of Alternative Nicotine Delivery Systems", September 22-24, 1997, in an attempt to reduce tobacco-related morbidity and mortality, it was recommended that nicotine replacement therapies be made more easily available than tobacco.

25 [0012] Smoking tobacco products amount to a rapid delivery mechanism of nicotine to the bloodstream since almost all of the nicotine absorbed from tobacco smoke reaches systemic circulation without the need to initially pass through liver. For this reason, conventional nicotine replacement therapies have been based on the use of a delivery system (e.g., transdermal, etc.) which will systemically deliver nicotine.

30 [0013] Unfortunately, current commercially available NRT's are relatively inconvenient to use and administer, and are not liked by many patients. For example, transdermal (e.g., transdermal, chewing gum, etc.) NRT's are associated with occasional skin irritation and chewing gum (and other buccal delivery systems) NRT's are perceived as having a bad taste. Further, transdermal and chewing gum NRT's are plagued by the delivery of inconsistent nicotine levels to the patient. Still further, alternative delivery NRT systems such as inhalers and nasal sprays have failed to achieve patient acceptability.

35 [0014] Of note is that, to the knowledge of the inventors, an oral nicotine replacement therapy is not currently commercially available. While not wishing to be bound by any particular theory or mode of action, the reason for this is believed to be as follows. Oral nicotine must first pass through the liver before entering the systemic circulation. As a result, extensive metabolism of nicotine occurs. In particular, oral nicotine is about 60-85 % metabolized from nicotine to continue by the liver so only 15-40% of oral nicotine reaches the systemic circulation (Benowitz, *et al.*, "Stable isotope studies of nicotine kinetics and bioavailability," *Clin. Pharmacol. Ther.*, 49(3):270-7 (2992); Svensson, "Clinical pharmacokinetics of nicotine," *Clin. Pharmacokinet.*, 12(1):30-40 (1987); and Zins, *et al.*, "Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration," *J. Clin. Pharmacol.*, 37(5):426-36 (1997)). Because the first-pass metabolism of nicotine is so effective and high concentrations of nicotine can not be used without irritating the digestive system, oral administration (e.g., a pill) has, heretofore, been an ineffective delivery system for nicotine. In light of this, there is no known effective oral nicotine replacement therapy. It would be desirable to have such a therapy since it would be much more convenient for the patient and would be more precisely controlled by the physician (eg., prescribing dosage based on body weight and related factors which are difficult to take into amount when prescribing nicotine patch or chewing gum).

50 SUMMARY OF THE INVENTION

55 [0015] The present inventors have found that variation in nicotine metabolism among individuals is due to variable expression of CYP2A isozymes; CYP2A6 has been shown to be the major nicotine metabolizing enzyme in human livers. Coumarin, a specific CYP2A6 substrate, was found to specifically and selectively inhibit nicotine metabolism to cotinine by $84\% \pm 11\%$ in test livers, and addition of orphenadine (a CYP2B6 inhibitor) enhanced the inhibition. Methoxsalen and tranlycypromine have also been found to be potent inhibitors of CYP2A6 and thus of nicotine to cotinine metabolism. The data indicate that variability in CYP2A6 expression results in inter-individual variation in nicotine metabolism, which in turn, can have behavioural consequences such as smoking more or less cigarettes. Therefore, inhibitors of CYP2A6 can be used to regulate nicotine metabolism, and in particular substantially decrease nicotine

metabolism, thereby affecting tobacco use.

[0016] Broadly stated, the present invention relates to the use of a CYP2A6 inhibitor to prepare a medicament for use contemporaneously with nicotine in the treatment of a condition requiring regulation of nicotine metabolism as specified in the claims.

[0017] The inventors have determined that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as "CYP2A6" for brevity) is predictive of an individual who: (i) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates.

[0018] This invention provides for the enhancement of oral nicotine therapy, such as oral administration of nicotine bitartrate, by nicotine metabolism through selective inhibition of CYP2A6, optionally with further selective inhibition of CYP2B6. Preferred inhibitors of CYP2A6 include tranlylcypromine.

[0019] This invention may be used to treat a condition requiring nicotine administration, preferably by administering the CYP2A6 inhibitor taken together with an oral formulation of nicotine, optionally also administering a CYP2B6 inhibitor. Preferred inhibitors of CYP2A6 include tranlylcypromine.

[0020] The present inventors have surprisingly found that several natural products, are inhibitors of the enzyme CYP2A. Accordingly, the present invention provides a method of inhibiting CYP2A6 comprising administering an effective amount of a natural product or an extract of a natural product to an individual in need thereof this method being useful in treating conditions requiring regulation of CYP2A6 activity. In one embodiment, the natural product is Hypericum or a Hypericum extract.

[0021] Other objects, features and advantages of the present invention will become apparent from the following detailed description. Aspects of this invention may be more fully described in one or more of U.S. Provisional Patent Applications Nos. 60/067,20; 60/067,021; 60/084,847; and 60/107,392.

[0022] It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only.

BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The invention will be better understood with reference to the drawings in which:

Figure 1 illustrates the results of a study showing CYP2A6 activity in heterozygous CYP2A6 individuals and wild-type CYP2A6 individuals as a function of time after administration of a CYP2A6 substrate;

Figure 2A-2D show chemical structures of some representative CYP2A6 inhibitors;

Figure 3 is a graph illustrating a correlation between fasted morning and non-fasted afternoon coumarin (C) testing sessions;

Figure 4 is a graph showing a time course of total 7-hydroxycoumarin concentration detected in the plasma of subjects given 100 mg of coumarin;

Figures 5 and 6 illustrate results of a study described in Example 1;

Figure 7 illustrates mean plasma nicotine concentrations in the study reported in Example 8;

Figure 8 illustrates current desire to smoke in the study reported in Example 8;

Figure 9 illustrates mean breath carbon monoxide in the study reported in Example 9;

Figure 10 illustrates the ratio of increased plasma nicotine to increased breath carbon monoxide in Example 9;

Figure 11 illustrates mean number of cigarettes consumed during the smoking period in Example 9;

Figure 12 illustrates the mean number of cigarette puffs taken in each 10-min. period during the smoking period in Example 9;

Figure 13 illustrates the mean latency period between the first two cigarettes in Example 9;

Figure 14 illustrates the mean grams of tobacco burned in Example 9.

Figure 15 illustrates the effect of CYP2A6 inhibitors methoxsalen and tranlylcypromine on increasing the bioavailability of nicotine supplied orally, with concomitant reduction in the desire to smoke.

Figure 16 is a graph illustrating the effect of Hypericum extracts on nicotine metabolism by expressed human cDNA CYP2A6.

Figure 17 is a graph showing the mean plasma concentration of nicotine versus time, in the presence of St. John's Wort or a placebo.

Figure 18 is a bar graph showing the mean plasma concentration of nicotine in the presence of St. John's Wort or a placebo.

Figure 19 are graphs illustrating effect of esculetin on nicotine metabolism by human liver micorsomes.

Figure 20 shows the chemical structure of various compounds found in natural products.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] As described in copending International patent application S.N. PCT/CA97/00506, inhibition of CYP2A6 (and optionally CYP2B6) inhibits the metabolism of nicotine. In particular, it was found that CYP2A6 is a major nicotine metabolizing enzyme in human livers and that by inhibiting CYP2A6 the metabolism of nicotine to cotinine in the liver is inhibited.

DIAGNOSTIC ASPECT

[0025] The present inventors have shown that individuals who carry CYP2A6 mutant alleles (i) have a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates.

[0026] In an aspect not forming part of the invention, but useful for understanding the invention there is provided a method for determining the risk of an individual for developing cancer may comprise determining the genotype or phenotype of CYP2A6 allele in the individual wherein the presence of a mutant allele is predictive of a decreased risk of smoking. Preferably, the CYP2A6 enzyme is CYP2A6.

[0027] Tobacco smoke contains a number of tobacco-specific procarcinogen nitrosamines, for example the N-nitroso-diethylamine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). These compounds are termed pro- or pre-carcinogens, as they are activated by the body. Specifically, these tobacco smoke procarcinogens can be activated by CYP2A6 (Crespi, et al., "Human cytochrome P450IIA3; cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1, *Carcinogenesis* 11(8):1293-1300 (1990); Yamazaki, et al., "Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes," *Carcinogenesis* 13(10):1789-94 (1992)). Therefore individuals who have CYP2A6 null alleles may also be less efficient at bioactivating tobacco smoke procarcinogens to carcinogens. This is of particular interest as ethnic variation in frequencies for CYP2A6 variant alleles exist (Nowak et al., 1998; Fernandez-Salguero P, et al., "A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A6 genes and identification of variant CYP2A6 alleles," *Am. J. Hum. Genet.*, 51(3):651-60 (1995); Yohi and Kamataki, 1998) and may be related to the ethnic differences in lung cancer incidence and histology (Groeger et al., 1997). Thus, individuals carrying CYP2A6 defective alleles may have a decreased risk of developing tobacco-related cancers and other medical complications for three reasons. 1) They have a decreased risk of becoming a smoker. 2) If they do become tobacco-dependent they smoke less than those without impaired nicotine metabolism resulting in lower exposures to tobacco-related procarcinogens (Law, et al., "The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer," *Br. J. Cancer* 75(11):1690-1693 (1997)). 3) They may activate fewer tobacco-related procarcinogens. These three factors suggest a significant reduction in tobacco-related cancers for carriers of a CYP2A6 defective allele(s).

[0028] In an aspect not forming part of the invention, but useful for understanding the invention, there is provided a method for determining the risk of an individual for developing cancer comprising determining the genotype or phenotype of a CYP2A6 allele in the individual wherein the presence of a mutant allele is predictive of a decreased risk-of smoking. Preferably, the CYP2A6 enzyme is CYP2A6.

[0029] The diagnostic aspect includes both phenotypic and genotypic methods for determining whether an individual has wild-type or mutant alleles for CYP2A6. The phenotypic assay may be performed by a metabolic study which is in effect an *in vivo* enzyme assay for CYP2A6 activity. This assay may be performed by administering a dose of a CYP2A6 substrate, for example nicotine or coumarin, and monitoring the physiological levels of the substrate and/or the product of enzymatic metabolism of the substrate in the individual at one or more time points during and subsequent to administration of the test dose. Typically, the levels will be measured in a biological fluid, such as blood, plasma, or urine, using well known assays for the particular components, examples of which are disclosed herein. An example of an *in vivo* phenotype and enzyme activity assay is provided in Example 3 below. This phenotypic assay can be used to classify individuals based on their normally expressed level of CYP2A6, which will correspond generally with the genotype of the individual as homozygous for fully active CYP2A6, heterozygous or homozygous for a lower activity allele, in decreasing order of nicotine metabolic rate.

[0030] The diagnostic aspect is also based on analysing a DNA-containing bodily sample from the individual for the presence of a mutant allele of human cytochrome P450 enzyme CYP2A6. As used throughout this specification, the term "mutant allele" is meant to encompass any allele having decreased or absent CYP2A6 activity. i.e., including null alleles. The presence of the mutant allele of CYP2A6 can be determined by conventional genotyping or phenotyping assays.

[0031] Many CYP2A6 alleles have been identified including, but not limited to, the wild-type allele (referred to throughout this specification as "CYP2A6*1"), and two defective or null mutant alleles ("CYP2A6*2" and "CYP2A6*3", respectively

(see, Fernandez-Salguero, et al. 1995), the contents of which are hereby incorporated by reference). The CYP2A6*2 allele differs from the wild-type allele by a single point mutation which leads to a leucine to histidine amino acid change at codon 1609. *in vitro* and *in vivo* studies have demonstrated that this allele is a null allele. Mutations in the CYP2A6*3 allele occur in exons 3, 6, and 8. Very recently an additional CYP2A6 allele was identified which consists of an entire CYP2A6 gene deletion (Nunoya K et al., 1998 "A new deleted allele the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). *Pharmacogenetics* 1998, 8: 239-249. Of course, additional mutant alleles which encode CYP2A6 enzymes with reduced activity may be found in individuals identified by the phenotypic and/or genotypic methods, and these individuals will also be expected to have lower risk of developing cancer and decreased risk of smoking.

[0032] The individual contemplated for the diagnostic methods (as well as the prophylactic and therapeutic methods described below) may be any type of mammal, but is preferably a primate, and more preferably a human.

[0033] Preferably, the bodily sample is a fluid such as blood or blood plasma. Alternatively, the bodily sample can be tissue. See, for example, Sambrook et al, *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press (1989), the contents of which are hereby incorporated by reference, for discussion of general assay techniques useful with the diagnostic methods described herein.

[0034] With reference to Figure 1, there is illustrated the result of CYP2A6 activity in a group (Group I) of individuals having heterozygous CYP2A6 activity (i.e. each individual in this group had a single mutant allele of CYP2A6 and a single active allele of CYP2A6) and a group of individuals (Group II) having wild type CYP2A6 activity (i.e. each individual in this group had two active alleles of CYP2A6). Blood plasma samples from each of the individuals in both groups were taken post-administration of coumarin (100 mg) at 35 minutes, 45 minutes and 75 minutes. Coumarin 7-hydroxylation was used to assess the compliment activity of CYP2A6. The results of the phenotyping assay clearly show that the Group I individuals have a significantly lower CYP2A6 activity (less than half at 35 and 45 minutes) than the Group II individuals.

[0035] Alternatively, the subject is an individual having a CYP2A6 genotype associated with an active form of the enzyme. The CYP2A6 genotype of an individual and the existence of an active CYP2A6 enzyme in an individual may be determined using procedures using techniques described herein. For example, coumarin 7-hydroxylation has been used to measure CYP2A6 activity (see, Cholerton, et al. (1992) and Rautio, et al. (1992)).

[0036] The recognition by the present inventors that CYP2A6 is the major nicotine metabolizing enzyme in human livers suggests that the enzyme can be assayed in an individual to determine the individual's risk of developing tobacco dependence. Determination of CYP2A6 levels may also be used to select and monitor in an individual appropriate conventional nicotine replacement therapies such as the nicotine patch and nicotine gum. It is unlikely that conventional nicotine replacement therapies (e.g. nicotine gum, nicotine patch, spray, pulmonary inhalation or other forms) will have a high success outcome if an individual has high levels of CYP2A6, although such individuals may be good candidates for enhanced NRT according to the methods described herein. Conversely, if an individual has very low levels of CYP2A6, administering nicotine at high dosages will likely result in increased toxicity, and side effects. Furthermore, the co-administration of a CYP2A6 inhibitor with an existing NRT would be expected to decrease the kinetics of nicotine from that source and to enhance the efficacy of the NRT (discussed below under Therapeutic Methods).

THERAPEUTIC ASPECTS :

[0037] As mentioned previously, the present invention relates to the treatment of conditions requiring a reduction in the activity of a CYP2A6 enzyme. In particular, the therapeutic aspect of the present invention relates to treatment and prevention of smoking, *in vivo* carcinogen formation and cancer in an individual. Each of this involves administration to an individual of a CYP2A6 inhibitor.

[0038] As used throughout this specification, the terms "smoking prevention" and "preventing smoking", as used throughout this specification, are intended to mean that the likelihood of the onset of smoking (i.e., the progression from a cigarette to regular smoking) in a current non-smoking individual (i.e., a person who has never smoked or is a ex-smoker) and the return to smoking of a previous smoker (i.e. relapse prevention) is substantially mitigated.

[0039] The terms "smoking regulation" and "regulating smoking", as used throughout this specification, are intended to mean that the amount smoked by a current smoking individual is reduced or, at least, fails to increase.

[0040] The terms "smoking treatment" or "treatment of smoking" means the stopping of all smoking or the reduction in amount of smoking as reflected in less use of tobacco products, a decrease in pattern of use or a decrease in tobacco smoke exposure. The measure of tobacco smoke exposure can be measured by analyzing breath carbon monoxide.

[0041] In an aspect, not forming part of the invention, but useful for understanding the invention, there is provided a method of regulating the formulation of a carcinogen in an individual comprising administering an effective amount of one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, translation of the gene encoding CYP2A, or both; (iii) substances which delete all or a portion of the gene encoding CYP2A. Preferably, the CYP2A is CYP2A6.

[0042] The terms "carcinogen formation regulation" and "regulating formation of a carcinogen", as used throughout this specification, are intended to mean that the occurrence of carcinogen formation in an individual is reduced. This may be achieved, for example, by using CYP2A6 inhibition to inhibit activation of procarcinogens present in the individual. As used throughout this specification, the term "procarcinogen" is meant to encompass any substance which is at least one of procytotoxic, promutagenic and progenotoxic ("pro" means the metabolite is more active than the parent compound).

[0043] In an aspect, not forming part of the invention, but useful for understanding the invention, there is provided a method of preventing cancer in an individual comprising administering an effective amount of one or more substances selected from the group consisting of (i) substances which inhibit CYP2A6 activity; (ii) substances which inhibit transcription, translation of the gene encoding CYP2A6, or both; (iii) substances which delete all or a portion of the gene encoding CYP2A6. Preferably, the CYP2A6 is CYP2A6.

[0044] The terms "cancer prevention" and "preventing cancer", as used throughout this specification, are intended to mean that the likelihood of the onset of cancer in a current cancer-free individual (i.e., a person who has never had cancer or whose cancer is in remission) is substantially mitigated.

[0045] The terms "inhibitor" and "inhibition", in the context of the present invention, are intended to have a broad meaning and encompass substances which directly or indirectly (e.g., via reactive intermediates, metabolites and the like) act on CYP2A6 to inhibit or otherwise regulate the ability of CYP2A6 to catalyze metabolism of a substrate. Other substances which act indirectly on CYP2A6 include those substances which inhibit transcription and/or translation of the gene encoding CYP2A6. In particular, the terms "CYP2A6 inhibition" and "CYP2A6 inhibitor" are intended to have a broad meaning and encompass any substance which: (i) inhibits CYP2A6 activity; (ii) inhibits transcription and/or translation of the gene encoding CYP2A6; or (iii) deletes or removes the gene encoding CYP2A6. Particularly preferred substances are those which alter the kinetics for metabolism of nicotine to cotinine, alter smoking behavior, alter the likelihood of addiction to smoking in a population of non-smokers, or alter the kinetics of formation for carcinogens whose formation from procarcinogens is catalyzed by CYP2A6, and more preferably exhibit the biological altering effect without producing other biological effects at significant levels.

[0046] A substance will "selectively" inhibit CYP2A6 activity when the substance can alter the kinetics for metabolism of nicotine to cotinine, alter smoking behavior, alter the likelihood of addiction to smoking in a population of non-smokers, or alter the kinetics of formation for carcinogens whose formation from procarcinogens is catalyzed by CYP2A6 generally at a dosage level which is lower than the dosage of the substance which is effective for production of another biological effect. For example, it is shown below that administration of methoxsalen acted to increase plasma levels of nicotine and to reduce desire to smoke in dependent smokers at levels that were one-fourth the therapeutic dose for treatment of psoriasis by methoxsalen.

[0047] The term "effective amount" as used herein means an amount effective and at doses and for periods of time necessary to achieve the desired results; this may mean limiting doses where the desired result is selective inhibition and selectivity is achieved through differential inhibition of CYP2A6.

CYP2A6 Inhibitors

[0048] As hereinbefore mentioned, in one of its aspects, the present invention relates to the regulation of nicotine metabolism to cotinine in an individual comprising selectively inhibiting CYP2A6. Inhibition of CYP2A6 may be achieved using one or more of the following (i) substances which inhibit CYP2A6 activity.

[0049] Substances which inhibit CYP2A6 activity include substances which specifically bind to CYP2A6 and thereby inhibit its activity.

[0050] Preferred inhibitors of CYP2A6 include tranlylcypromine, esculetin and selegiline.

[0051] See Figures 2A to 2D for the chemical structures of these inhibitors. Selective and non-selective monoamine oxidase inhibitors (e.g., selegiline) are particularly preferred. Various isomers of the above compounds which can be shown to inhibit CYP2A6 as described below are within the contemplation of this invention.

[0052] Derivatives and analogs of these substances may also be used in the of the invention. Derivatives and analogs include compounds that are structurally similar to the compounds described herein and can bind to the CYP2A6 active site. For example, derivatives of tranlylcypromine include pharmaceutically acceptable salts, esters and complexes of tranlylcypromine including potassium and sodium salts, and amino acid, carbohydrate and fatty acid complexes.

[0053] The present inventors have surprisingly found that natural products and extracts of natural products inhibit CYP2A6 activity in both human liver microsomes and pure full-length human cDNA expressed cytochromes. Accordingly, CYP2A6 inhibitors of the present invention include natural products or extracts of a natural product capable of inhibiting CYP2A6, such as Hypericum or a Hypericum extract.

[0054] The term "Hypericum" as used herein as synonymous with *Hypericum perforatum*, St. John's Wort, Goatweed and Klamath Wee. The phrase "Hypericum or an extract of Hypericum" as used herein includes the whole plant *Hypericum perforatum* or a derivative, extract, isolate or purified component thereof that can inhibit CYP2A6 activity. This includes

natural components of the plant and synthetic analogues. A preferred extract of *Hypericum* is a methanol extract.

[0055] Derivatives of *Hypericum* which may be used in the methods and compositions of the invention include hypericin, pseudohypericin, quercetin, hyperoside, quercitrin, isoquercitrin, rutin, campherol, luteolin, 13-118-biopigenin, 1,3,6,7-tetrahydroxyxanthone, procyanidines, hyperforin, ethereal oil, phenol carbonic acids (e.g. chlorogenic acid), xanthone, phenylpropanes, flavonol derivatives, biflavones, proanthocyanidins, xanthenes, phloroglucinols, naphthodianthrones and essential oil constituents. Also included are the pharmaceutically acceptable salts, esters and complexes of the derivatives including potassium and sodium salts, and amino acid, carbohydrate and fatty acid complexes. Suitable derivatives of *Hypericum* may be selected based upon their ability to inhibit CYP2A6 with greater than 50% inhibition, and/or a K_i less than 300 μM .

[0056] The ability of a substance to selectively inhibit CYP2A6 and thus regulate nicotine metabolism to cotinine may be confirmed using the methods described herein for screening for an inhibitor.

[0057] In one embodiment of the invention, the CYP2A6 inhibitor is at least one member selected from the group comprising tranlylcypromine, derivatives thereof and analogs thereof (see Figure 2A).

CYP2B6 Inhibitors

[0058] CYP2B6 inhibitors may also be used in combination with inhibitors of CYP2A6 to provide an enhanced inhibitory effect. Inhibitors of CYP2B6 include one or more of the following (i) substances which inhibit CYP2B6 activity; or (ii) substances which inhibit transcription and/or translation of the gene encoding CYP2B6. CYP2B6 inhibitors may also be used alone to inhibit nicotine metabolism in an individual.

[0059] Substances which inhibit CYP2B6 activity include substances which specifically bind to CYP2B6 and thereby inhibit its activity. Examples of such substances include antibodies which are specific for CYP2B6 including for example, commercially available antibodies such as anti-CYP2B6 sold by Gentest Corporation, Woburn, Mass., U.S.A.

[0060] Substances which inhibit CYP2B6 activity also include substances selected from phenylethyl amines, diphenylbarbiturates, diethyl substituted barbiturates and hydantoins. In particular, diphenhydramine and its derivatives, including orphenadrine (The Merck Index. No. 6831), and derivatives or analogs of orphenadrine, and other antihistamines, anticholinergic substances such as cholines and analogs and derivatives thereof may be used as CYP2B6 inhibitors in various embodiments of the methods and compositions of the invention. Antibodies, such as polyclonal CYP2B1/2, polyclonal CYP2B1 and polyclonal CYP2B6 sold by Gentest Corporation, Woburn, Mass., U.S.A., also bind specifically to CYP2B6 such that they also inhibit the activity of CYP2B6.

[0061] Derivatives of orphenadrine which may be used in the methods and compositions of the invention include pharmaceutically acceptable salts, esters and complexes of orphenadrine including potassium and sodium salts, and amino acid, carbohydrate and fatty acid complexes. In one embodiment, suitable analogs of orphenadrine may be selected based upon their functional similarity to orphenadrine, including the ability to inhibit CYP2B6. Analogs of orphenadrine may also be selected based upon their three dimensional structural similarity to orphenadrine.

[0062] Substances which inhibit transcription and/or translation of the gene encoding CYP2B6 include a nucleic acid sequence encoding the CYP2B6 gene (see Figure 2B, GenBank Accession No. HSP452B6 for the mRNA sequence of CYP2B6), or parts thereof (e.g., the region which is on either side of nucleotide 9 (ATG), and the sites 111, 274, 424, 585, 762, 904, 1092, and 1234 nt), inverted relative to their normal orientation for transcription - i.e., antisense CYP2B6 nucleic acid molecules. Such antisense nucleic acid molecules may be produced and introduced into cells using conventional procedures as described herein.

[0063] CYP2B6 may also be selectively inhibited in an aspect of the invention by interfering with the transcription of the gene encoding CYP2B6 using conventional gene transfer methods as discussed herein.

[0064] In preferred embodiments of the invention the CYP2B6 inhibitor employed is orphenadrine and derivatives or analogs of orphenadrine.

[0065] An inhibitor of CYP2A6 or CYP2B6 may be targeted to the enzyme using antibodies specific to an epitope of the enzyme. For example, bispecific antibodies may be used to target an inhibitor. The bispecific antibodies contain a variable region of an antibody specific for at least one epitope of CYP2A6 or CYP2B6, and a variable region of a second antibody which is capable of binding to an inhibitor. The bispecific antibodies may be prepared by forming hybrid hybridomas, using procedures known in the art such as those disclosed in Staerz, et al. ("Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity," Proc. Natl. Acad. Sci. USA, 83(5):1453-7 (1986)) and Staerz, et al. (Immunology Today, 7:241 (1986)). Bispecific antibodies may also be constructed by chemical means using conventional procedures such as those described by Staerz, et al. ("Hybrid antibodies can target sites for an attack by T cells," Nature, 314(6012):628-31 (1985)) and Perez, et al. ("Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody," Nature, 316(6026):354-6 (1985)), or by expression of recombinant immunoglobulin gene constructs.

Nicotine Replacement Therapy

5 [0066] An oral nicotine replacement therapy containing nicotine alone would be ineffective due to the extensive metabolism of nicotine in the liver which significantly decreases the systemic availability of the nicotine. However, administering the nicotine with a CYP2A6 inhibitor would increase the bioavailability and the effectiveness of the oral nicotine therapy.

10 [0067] As used herein, "contemporaneous administration" of two substances to an individual means providing each of the two substances so that they are both biologically active in the individual at the same time. The exact details of the administration will depend on the pharmacokinetics of the two substances in the presence of each other, and can include administering the two substances within a few hours of each other, or even administering one substance within 24 hours of administration of the other, if the pharmacokinetics are suitable. Design of suitable dosing regimens are routine for one skilled in the art, in view of the details provided herein on the biological activities of CYP2A6 substrates and inhibitors. In particular embodiments, two substances will be administered substantially simultaneously, i.e., within minutes of each other, or in a single composition that contains both substances. On the other hand, a CYP2A6 inhibitor which acts by deleting or removing the gene encoding CYP2A6 could be administered months or even years before administration of nicotine or a procarcinogen that would otherwise be converted to a carcinogen by CYP2A6, and the effects due to the two administrations may still be contemporaneous.

20 Compositions

[0068] Substances which inhibit CYP2A6 activity described in detail herein, may be incorporated into pharmaceutical compositions. Therefore the specification describes a pharmaceutical composition for use in treating a condition requiring a reduction in the activity of a CYP2A6 enzyme comprising an effective amount of one or more substances which selectively inhibit CYP2A6, nicotine, and a pharmaceutically acceptable carrier, diluent, or excipient. In one of its aspects, 25 the specification describes a pharmaceutical composition for use in smoking prevention, smoking treatment, smoking regulation, regulating carcinogen formation, cancer prevention and/or cancer treatment. Further, the compositions may also be used together with other active compounds, including such other active compounds which are susceptible to CYP2A6-mediated metabolism leading to an inhibition or reduction in effectiveness of the other active compound.

30 [0069] Conditions requiring regulation of nicotine metabolism to cotinine include nicotine use disorders- i.e, dependent and non dependent tobacco use, and nicotine-induced disorders - i.e., withdrawal. The conditions may develop with the use of all forms of tobacco (e.g., cigarettes, chewing tobacco, snuff, pipes, and cigars) and with prescription medications (e.g. nicotine gum, nicotine patch, spray, pulmonary inhalation or other forms). In particular, the pharmaceutical compositions and treatment methods of the invention may be used to diminish a subjects desire to smoke and thereby alter smoking behaviour. The pharmaceutical compositions and uses of the invention may also be used together with other 35 centrally active pharmaceutical compositions that modify smoking behaviour (e.g. bupropion (a.k.a. Wellbutrin®) in its various formulations), to decrease the dose of the centrally active composition or to increase its effectiveness in the treatment of tobacco dependence.

40 [0070] The compositions and uses by regulating nicotine metabolism in an individual are highly effective. The uses and compositions maintain the behavioural components of smoking and modify them by reducing nicotine metabolism to cotinine. An individual with reduced nicotine metabolism following administration of a composition of the present invention, will alter smoking behaviour and smoke exposure because of modification of nicotine requirements. The uses and compositions of the invention show patterns of reduction, more sustained abstinence, and lower tobacco smoke exposure than obtained with prior art methods in particular those using nicotine deprivation.

45 [0071] The behavioural component of smoking is particularly important in some groups of individuals, and thus the uses and compositions of the invention in modifying and maintaining behavioural components may be particularly useful in reducing smoking in those individuals. For example, it has been found that behavioural components are significant in tobacco use by women. The present invention permits the development of behavioural learning on an individual/or group basis.

50 [0072] The compositions and uses are also particularly suited to regulate nicotine metabolism in individuals or populations having high levels of CYP2A6. For example, Caucasians in North America have high levels of CYP2A6. An individual or population having a high level of CYP2A6 can be identified using our methods for measuring CYP2A6.

55 [0073] The compositions and uses also have the advantage of individualization and flexibility in treatment duration. The compositions and uses are particularly suitable for severely dependent individuals, previous treatment failures, individuals unable to accept the current approach of complete cessation, treatment/prevention of relapse, or concurrent treatment with other uses such as the nicotine patch. It is expected that the compositions and uses of the invention will decrease the doses of nicotine patch and all other forms of nicotine replacement therapies that are needed and will prolong the duration of action of the therapy and/or enforce their effectiveness in the treatment of tobacco dependence.

[0074] The uses and compositions in treating individuals with nicotine use disorders and nicotine induced disorders

are also useful in the treatment of diseases or conditions, including nicotine-related disorders such as opioid -related disorders; proliferative diseases; cognitive, neurological or mental disorders; and other drug dependencies in the individuals. Examples of such underlying diseases or conditions include malignant disease, psychosis, schizophrenia, Parkinson's disease, anxiety, depression, alcoholism, opiate dependence, memory deficits, ulcerative colitis, cholinergic deficits, and the like.

[0075] The uses and compositions may also be used in the treatment of individuals having a condition which requires a reduction in CYP2A6 or CYP2B6. For example, CYP2A6 is known to metabolize several procarcinogens such as NNK (Crespi CL, et al., "A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6," *Carcinogenesis*, 12(7): 1197-201 (1991)), aflatoxin B1 (Yun CH, et al., "Purification and characterization of human liver microsomal cytochrome P-450 2A6," *Molec. Pharmacol.*, 40(5):679-85 (1991)); hexamethylphosphoramide (Ding X, et al., "Mossbauer studies on the metal-thiolate cluster formation in Fe(II)-metallothionein," *Eur. J Biochem.*, 171(3):711-4 (1988)), and nitrosodimethylamine (Davies RL, et al., "Development of a human cell line by selection and drug-metabolizing gene transfection with increased capacity to activate promutagens," *Carcinogenesis*, 10:865-891 (1989); Fernandez-Salguero, et al. (1995)). Therefore, inhibitors of CYP2A6 may be useful in the prophylaxis (e.g., inhibition of CYP2A6 substrates thereby decreasing genotoxicity, cytotoxicity and/or mutagenicity) and treatment of malignant diseases, and, without limitation, the above-mentioned conditions and diseases.

Formulation and Dosing

[0076] The pharmaceutical compositions of the invention contain substances which inhibit CYP2A6 described in detail herein or substances identified using the methods of the invention. The active substances can be administered alone, but are generally administered with a pharmaceutical carrier etc. (see below), selected on the basis of the chosen route of administration and standard pharmaceutical practice.

[0077] The dosage administered will vary depending on the use and known factors such as the pharmacodynamic characteristics of the particular substance, and its mode and route of administration; age, health, and weight of the individual recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.

[0078] In some instances, instead of increasing the dosage of a compound, the kinetics of inhibition created by certain chemical compounds can be altered or enhanced by adding to the treatment protocol a second inhibitor to a substance (e.g., enzyme) that is capable of inhibiting the metabolism of the CYP2A6 inhibitor. By adding such a second inhibitor, the quantity of the CYP2A6 inhibitor will be maintained thus prolonging the beneficial effect of maintaining an elevated plasma concentration of nicotine. The use of such a second inhibitor is very beneficial since it facilitates treatment of individuals by maintaining substantially constant nicotine levels and acting locally on the kinetics of the CYP2A6 inhibitor. By using this approach, large dosages of centrally active compounds can be avoided.

[0079] Similarly, preexposure of an individual to an inhibitory substance sometimes can result in an inhibitory effect that will outlast the presence of the drug in the plasma or that will have a persistent effect in the individual despite the inhibitor's half life in the plasma. This phenomenon caused by preincubation or preexposure of an inhibitory substance can help increase the dose interval at which a dosage of the substance must be administered, decrease the chronic dose or enhance CYP2A6 inhibition. Furthermore, preexposure of an individual to one inhibitory substance can subsequently decrease the needed dose of a second inhibitor.

[0080] The appropriate dosage of a substance which selectively inhibits CYP2A6 is dependent upon the amount of CYP2A6 that is present in an individual's body. This amount is in turn dependent upon whether the individual contains two mutant alleles, one mutant allele or no mutant alleles at the CYP2A6 gene locus. In Example 1, we confirmed that such variations can exist in the genetic material of a population. Therefore, in an aspect not forming part of this invention, but useful for understanding the invention, there is provided a method for determining the CYP2A6 activity in an individual containing two mutant alleles, one mutant allele or no mutant alleles at a gene locus for the CYP2A6 gene; the method comprising the steps of:

- (a) assaying a bodily sample containing deoxyribonucleic acid (i.e. a "DNA-containing bodily sample") from the individual to determine whether the individual contains two mutant alleles, one mutant allele or no mutant alleles at the CYP2A6 gene locus;
- (b) determining the amount of CYP2A6 present in the individual; and
- (c) correlating the results of assaying in step (a) and the amount of CYP2A6 in step (b) to determine an appropriate dosage for that individual of a substance which (i) selectively inhibits CYP2A6 activity, or (ii) selectively inhibits transcription and/or translation of the gene encoding CYP2A6.

[0081] The individual recipient may be any type of mammal, but is preferably a human. Generally, the recipient is an

individual having a CYP2A6 genotype associated with an active form of the enzyme. The CYP2A6 genotype of an individual and the existence of an active CYP2A6 enzyme in an individual may be determined using procedures described herein. For example, coumarin 7-hydroxylation has been used to measure CYP2A6 activity (Cholerton, et al. (1992); and Rautio, et al., (1992)). As discussed above, the methods and compositions of the invention may be preferably used in individuals or populations having high levels of CYP2A6, or in individuals where the behavioural components of smoking are significant.

[0082] For use in the treatment of conditions requiring regulation of nicotine metabolism to cotinine, by way of general guidance, a daily oral dosage of an active ingredient such as coumarin or methoxsalen can be about 0.01 to 80 mg/kg of body weight, preferably 0.01 to 20, more preferably 0.05 to 3 mg/kg of body weight. Ordinarily a dose of 0.03 to 50 mg/kg of coumarin, methoxsalen or tranlycypromine per day in divided doses one to multiple times a day, preferably up to four times per day, or in sustained release form is effective to obtain the desired results. In accordance with a particular regimen, coumarin or methoxsalen or tranlycypromine is administered once to four times daily for as long as necessary. While standard interval dose administration may be used the compositions of the invention may be administered intermittently prior to high risk smoking times, e.g., early in the day and before the end of a working day.

[0083] More than one substance described in detail herein or identified using the methods of the invention may be used to regulate metabolism of nicotine to cotinine. In such cases the substances can be administered by any conventional means available for the use in conjunction with pharmaceuticals, either as individual separate dosage units administered simultaneously or concurrently, or in a physical combination of each component therapeutic agent in a single or combined dosage unit. The active agents can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice as described herein.

[0084] The substances for the present invention can be administered for oral, topical, rectal, parenteral, local, inhalant or intracerebral use. In an embodiment of the invention, the substances are administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using forms of transdermal skin patches known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will be continuous rather than intermittent throughout the dosage regimen. The substances can also be administered by way of controlled or slow release capsule system and other drug delivery technologies.

[0085] For example, for oral administration in the form of a tablet or capsule, the active substances can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral active substances can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Suitable binders, lubricants, disintegrating agents, and colouring agents can also be incorporated into the dosage form if desired or necessary. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Suitable lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Examples of disintegrators include starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

[0086] Gelatin capsules may contain the active substance and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar carriers and diluents may be used to make compressed tablets. Tablets and capsules can be manufactured as sustained release products to provide for continuous release of active ingredients over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration may contain colouring and flavouring agents to increase patient acceptance.

[0087] Water, a suitable oil, saline, aqueous dextrose, and related sugar solutions and glycols such as propylene glycol or polyethylene glycols, may be used as carriers for parenteral solutions. Such solutions also preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Suitable stabilizing agents include antioxidizing agents such as sodium bisulfate, sodium sulfite, or ascorbic acid, either alone or combined, citric acid and its salts and sodium EDTA. Parenteral solutions may also contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

[0088] The substances described in detail herein and identified using the methods of the invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

[0089] Substances described in detail herein and identified using the methods of the invention may also be coupled with soluble polymers which are targetable drug carriers. Examples of such polymers include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmeth-acrylamidophenol, polyhydroxyethylaspartamidophenol, or polyethyl-eneoxide-polylysine substituted with palmitoyl residues. The substances may also be coupled to biodegradable polymers useful

in achieving controlled release of a drug. Suitable polymers include polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels. The substances can also be affixed to rigid polymers and other structures such as fullerenes or Buckeyballs.

[0090] Pharmaceutical compositions suitable for administration contain about 1 milligram to 1500 milligrams of active substance per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

[0091] Suitable pharmaceutical carriers and methods of preparing pharmaceutical dosage forms are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

Co-administration with Oral Nicotine

[0092] In a particular embodiment, it has been found that specific inhibitors of CYP2A6, preferably tranlycypromine, are particularly effective inhibitors of CYP2A6 and of the metabolism of an oral formulation of nicotine and as such, enhance the effect of oral nicotine replacement therapies. In other words, it has been found that these inhibitors are effective in inhibiting nicotine metabolism and thereby increasing plasma concentrations of nicotine, particularly when the nicotine is orally ingested thereby enhancing oral nicotine replacement therapies.

[0093] Thus, this specification describes a composition for enhancing the effect of oral nicotine replacement therapy, comprising an inhibitor of CYP2A6 and nicotine formulated for oral ingestion. The substances described in detail herein, together with nicotine, form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, consistent with conventional pharmaceutical practices.

[0094] Those of skill in the art will recognize that oral formulation within the invention can be in the form of: (i) a single composition comprising both the CYP2A6 inhibitor and nicotine, or (ii) a kit comprising independently administered compositions comprising the CYP2A6 inhibitor and nicotine, respectively. For independently administered compositions, the administration is preferably substantially contemporaneous. When the preferred CYP2A6 inhibitors tranlycypromine are administered with oral formulations of nicotine the plasma concentrations of nicotine have increased over the plasma concentrations when nicotine is orally digested without administering the CYP2A6 inhibitor(s).

Combination of inhibitors

[0095] The combination of an CYP2A6 inhibitor (and a CYP2B6 inhibitor (e.g., orphenadrine) enhances inhibition of nicotine metabolism to cotinine. Thus, a preferred embodiment of the invention provides the use of an effective amount of a CYP2A6 inhibitor and an effective amount of a CYP2B6 inhibitor to selectively inhibit nicotine metabolism to cotinine in the manufacture of a medicament for use contemporaneously with nicotine treating conditions requiring regulation of nicotine metabolism to cotinine. The inhibitors may be administered concurrently, separately or sequentially. Preferably, the administration of the inhibitors is substantially contemporaneous. The doses of the CYP2A6 inhibitor and the CYP2B6 inhibitor are each selected so that each inhibitor alone would not show a full effect. The effective doses are those which are approximately the minimum doses adequate for enhanced inhibition of nicotine metabolism to cotinine. The combination of inhibitors is administered substantially contemporaneously with a source of nicotine, preferably nicotine formulated for oral administration. Pharmaceutical compositions containing combinations of CYP2A6 and CYP2B6 inhibitors may be prepared and administered as described herein for the compositions containing CYP2A6 inhibitors. The pharmaceutical compositions preferably contain methoxsalen or an analog or derivative thereof, and orphenadrine, or an analog or derivative thereof, in concentrations of 1 to 1500 mg, and 25 to 400 mg, respectively.

[0096] Embodiments of the present invention will be illustrated with reference to the following examples.

EXAMPLES

EXAMPLE 1

Epidemiology Study

[0097] We examined the prevalence of CYP2A6 gene mutations in 126 tobacco dependent Caucasian smokers and 143 Caucasian individuals who had tried smoking, but who had never become tobacco dependent smokers (eg., exposure controls). The objectives were two fold. The first was to determine the incidence of individuals who were deficient in CYP2A6 activity (e.g., homozygous for null CYP2A6 alleles). The second was to determine if slower CYP2A6 mediated nicotine metabolism, due to having null CYP2A6 alleles, decreased the chances of becoming a tobacco dependent smoker.

[0098] In this Example a study was conducted to assess the CYP2A6 genotype in a group of individuals and the effect of the CYP2A6 on the smoking behaviour of the individuals.

[0099] Subjects were unrelated healthy individuals each with 4 Caucasian grandparents and were divided into three groups. The first group comprised tobacco Dependent only (TD, DSM-IV ("DSM"=Diagnostic Statistician Manual of the American Psychiatric Association)) subjects including 76 males aged 19 to 52 years old (mean (SD): 31.1 years old (8.5 years)), and 57 females aged 20 to 70 years old (mean (SD): 31.4 years old (10.2)). The second group comprised Alcohol and Tobacco Dependent (AT, DSM-IV) subjects including 60 males aged 17 to 61 years old (mean (SD): 37.2 years old (9.94 years)), and 10 females aged 19 to 66 years old (mean (SD): 41.4 years old (11.89 years)). The third group was an exposure control group consisting of Never-Tobacco Dependent (NTD(subjects, who had previously tried smoking, but had never become dependent. This group included 86 males 19 to 59 years old (mean (SD): 29.2 years old (8.6 years)), and 77 females 19 to 58 years old (mean (SD): 27.4 years old (8.4 years)). All subjects completed a drug questionnaire and tobacco module (Heatherton, et al., "The Fagerstrom Test for nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire," Br. J. Addict., 86(9):1119-1127 (1991)). All subjects had no other psychoactive drug dependencies, including alcohol (except of course for the AT group).

[0100] CYP2A6 genotyping of each subject was performed on genomic DNA isolated from peripheral leukocytes as described by Fernandez-Salguero, et al. (1995). Briefly, the assay consisted of a CYP2A6 gene-specific nested PCR amplification followed by a RFLP analysis.

Materials and Methods:

Primers used for PCR genotyping assays:

[0101]

Table 2

Assay	Name	Sequence (5'-3')
<i>CYP2A6*2</i> (v_1) and <i>CYP2A6*3</i> (v_2)	F4	CCTCCCTTGCTGGCTGTGTCCCAAGCTTAGGC
	R4	CGCCCCTTCCTTTCCGCCATCCTGCCCCAG
	E3F	GCGTGGTATTCAGCAACGGG
	E3R	TCGTGGGTGTTTTCTTC

CYP2A6 Genotype

[0102] DNA is extracted from blood samples and quantified using routine extraction procedures. CYP2A6 genotype was determined using nested PCR and RFLP as described by Fernandez-Salguero, et al. (1995). The first amplification, which is CYP2A6 gene-specific, was used to increase the specificity for the CYP2A6 gene (versus other CYP2A genes). Exon 3 was utilized in the second amplification because both the *CYP2A6*2* and *CYP2A6*3* mutant alleles contain nucleotide changes leading to amino acid changes in this region of the CYP2A6 gene.

[0103] The first amplification was performed using the XL-PCR kit (Parkin-Elmer Co., Norwalk, Connecticut). A 100 μ l reaction mixture of 0.2 μ M of primer F4 and R4, 200 μ M dNTPs, 0.8 mM magnesium acetate, and 2 U of rTth1 DNA polymerase and 400 to 600 ng of genomic DNA used. The amplification was performed in a MJ DNA Engine (MJ Research, Inc., Watertown, Massachusetts) at 93°C for 1 minute, 66°C for 6 minutes and 30 seconds for 31 cycles.

[0104] The second amplification was performed in a reaction mixture containing 0.5 μ M of primers E3F and E3R, 200 μ M dNTPs, 1.5 mM MgCl₂, 2.5 U of Taq DNA polymerase (Gibco BRL, Life Technologies, Burlington, Ontario), and 2.5 μ l of first amplification product, which was the template for the reaction. The reaction conditions were as follows: 94°C for 3 minutes, followed by 31 cycles of 94°C for 1 minute, 60°C for 1 minute and 72°C for 1 minute.

[0105] The second amplification yielded a PCR product 201 bp in length which was digested with Xcm I (New England Biolabs) and Dde I (New England Biolabs and Pharmacia Biotech) to detect the *CYP2A6*2* and *CYP2A6*3* mutations, respectively (cutting indicates the presence of the mutation). Concentrations of enzymes and PCR product, total volume and digestion time were determined empirically to optimize cutting efficiency with a minimal amount of time and enzyme. Xcm I digestion reactions were carried out at 37°C for 2 hours in a 30 μ l reaction mixture containing 1X NEBuffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM DTT pH 7.9 @ 25°C), dH₂O, and 2 U of Xcm I. Dde I digestions were carried out at 37°C for 2 hours in a 30 μ l reaction mixture containing One-Phor-All (OPA) buffer (Pharmacia Biotech) and 2 U of Dde I. Digestion products were analysed on ethidium-stained 3% agarose gels.

[0106] Blood samples were obtained under consent from all subjects. Positive controls were donated by Drs. P. Fernandez-Salguero and H. Raunio. Negative controls used water in place of genomic DNA. Every genotyping reaction

carried four randomly selected samples from a previous reaction to check for reproducibility.

[0107] Chi-Square tests were performed comparing distribution of CYP2A6 genotypes and alleles between groups (SAS). F-tests (check for unequal variance [SAS]), followed by a two-sample t-test (SAS) were used in comparing smoking patterns within smokers. Significance was at 5%.

[0108] It was postulated that individuals with impaired nicotine metabolism (i.e., carriers of at least one CYP2A6 defective or mutant allele) would experience greater aversive effects due to higher nicotine levels and not become smokers or would smoke at a decreased level when compared to individuals with active nicotine metabolism (i.e., individuals having CYP2A6*1/CYP2A6*1 genotype). Specifically, it was hypothesized that there would be an under-representation of individuals carrying defective CYP2A6 alleles in a tobacco dependent population.

[0109] With reference to the results of the study, among the total dependent smokers (TD + AT), the frequency of individuals carrying 1 or 2 of the CYP2A6 defective alleles was lower than in the exposure control group (NTD): 13.3% vs. 20.2%, $p=0.076$, χ -square; Odds Ratio of 1.66, C.I. 0.95-2.89 - see Figure 5. Further, both the CYP2A6*2 and CYP2A6*3 allele frequencies were lower in the dependent smokers (TD and AT) than in the exposure control group (NTD): CYP2A6*2: 3.0% versus 3.1% and CYP2A6*3: 4.4% versus 7.7% - see Figure 5.

[0110] We further postulated that, within the group of those who smoke, those with deficient nicotine metabolism (i.e., carriers of at least one CYP2A6 defective or mutant allele) would smoke fewer cigarettes.

[0111] With further reference to the results of the study, within the TD group, those subjects which were homozygous for CYP2A6 active alleles smoked significantly more cigarettes per day and per week when compared with smokers who were heterozygous carrying a single CYP2A6 defective allele (i.e., one or both of CYP2A6*2 and CYP2A6*3): 23 versus 19 cigarettes per day, t test $P=0.02$, 125 versus 161 cigarettes per week, t test $P=0.009$ - see Figure 6.

[0112] As discussed above, nicotine is important in establishing and maintaining tobacco dependence; variability in nicotine pharmacokinetics could have a profound influence on whether individuals become smokers. The data produced in this study demonstrates an under-representation of individuals carrying 1 or 2 of the CYP2A6 defective alleles in a tobacco dependent population (TD + AT) when compared to a never tobacco dependent (NTD) control population. While not wishing to be bound by any particular theory or mode of action, this may be caused when individuals who carry CYP2A6 defective alleles, upon smoking, experience higher nicotine levels and greater aversive effects to the nicotine. As a result, the individual may discontinue smoking and be less likely to become tobacco dependent. Therefore, the data produced in this study indicates that individuals who carry 1 or 2 of the CYP2A6 defective or mutant alleles, and who try smoking, are at lesser risk for becoming tobacco dependent than individuals who have two active CYP2A6 alleles.

[0113] Further, as discussed above, it is well known that dependent smokers adjust their smoking behaviour in order to maintain blood and brain nicotine concentrations, and thus, variable nicotine metabolism could play a role in altering smoking patterns. The observation that dependent smokers who carry a single defective CYP2A6 allele smoke significantly fewer cigarettes when compared to homozygous wild-type smokers indicates that nicotine metabolism, as mediated by CYP2A6, is a significant determinant in the amount that dependent smokers smoke. In other words, heterozygosity in a single gene, namely the CYP2A6 gene, is affecting this complex drug taking behaviour.

[0114] The clinical implications of CYP2A6 genotype on tobacco dependence and smoking behaviour disclosed herein are widespread. Individuals who carry CYP2A6 defective alleles may have a decreased risk for cancer development because they have a decreased risk of becoming tobacco-dependent smokers. If they do become dependent smokers, the data produced in this study demonstrates that they would smoke less than those homozygous for active CYP2A6 alleles. There is clear evidence that the amount of tobacco smoked is related to increased risk for lung cancer (Law, et al. 1997)) - see Figure 6

[0115] In addition, tobacco smoke contains a number of tobacco specific procarcinogen nitrosamines, such as N-nitrosodialkylamines - e.g., N-nitrosodiethylamine (the Merck Index, No. 6557), N-nitrosodimethylamine (The Merck Index, No. 6558) and 4-methylnitrosamino-1- β -pyridyl-1-butanone (Crespi, et al. 1990; Yamazaki, et al. 1992). As these procarcinogens can be activated by CYP2A6, individuals who carry CYP2A6 defective alleles will be advantageously inefficient at bioactivating tobacco smoke procarcinogens to carcinogens.

[0116] Thus, in summary the data produced in the study of this Example demonstrates that a single genetically polymorphic gene, the CYP2A6 gene, is related, and in some cases predictive, of whether an individual becomes a smoker. In addition, if an individual becomes dependent on tobacco alone, the CYP2A6 gene variants alter the number of cigarettes that he/she smokes. Accordingly, the CYP2A6 genotype directly influences the risk for tobacco dependence, alters the amount of tobacco consumed, and plays a role in tobacco-related cancer susceptibility.

[0117] One envisaged application of the present invention is the genetic identification of an individual's risk for smoking and related cancers. Identification of high and low risk individuals will allow targeted prevention, treatment and education. Specifically this will involve the identification of an individual with a high and low risk for: (i) becoming a smoker (if the individual is a non-smoker), (ii) higher tobacco-consumption (if the individual is a smoker), and (iii) CYP2A6-related cancers.

EXAMPLE 2**Coumarin Phenotyping Test and CYP2A6 Genotyping Test**5 **A. Coumarin Test**

[0118] Coumarin is a selective and specific substrate for human CYP2A6 and can be used to: (1) identify individuals who are potential therapeutic exclusions for use of CYP2A6 inhibitors; (2) for dosage refinement based on the initial level of activity of CYP2A6; and (3) for risk factor assessment in identifying individuals who will not benefit from the treatment or who may be at risk to toxicity from agents which are inhibitors and substrates themselves of CYP2A6. The Coumarin Test exists in two forms:

(1) Coumarin Test When Only Urine is Available

15 [0119] Coumarin 5 mg formulated in a capsule or other dose form is administered orally to fasted individuals after voiding of residual bladder urine. Urine is collected for the first 2 hours and for the subsequent 6 hours. The amount of urinary excretion of the coumarin metabolite 7 hydroxy-coumarin (free and conjugated) is determined by determining the concentration of these metabolites on the urine using an HPLC assay as described in an earlier example. The relative activity of CYP2A6 is reflected in the total amounts of 7 hydroxy-coumarin excreted in the sampling periods separately and combined and the activity can be expressed as the ratio of the percent coumarin excretion (amount excreted in the first 2 hours/amount excreted in 8 hours) x 100. This percent excretion ranges from values less than 20% in individuals without CYP2A6 activity to > 80% in individuals with high activity. This test can be equally effectively and reliably be applied to smokers and non-smokers and may be used at any time of day with out apparent effect of the smoking condition or time of day on the results. The test demonstrates high within subject reproducibility with a linear r of > 0.9. See Figure 3 for results of a study in which smokers and nonsmokers were given coumarin in the morning and afternoon on each of 2 separate days. High within subject reproducibility and reliability is demonstrated.

(2) Coumarin Test When Plasma Samples Can Be Taken

30 [0120] In some clinical situations blood samples can be easily taken or are necessary as part of other clinical tests. In this situation, a plasma-based test of CYP2A6 activity has been developed and applied to individuals of known genotype. Individuals ingest coumarin 5.0 mg orally and 45 minutes later a blood sample is drawn in a heparinized (or other anticoagulant containing tube). The sample is spun and the plasma separated. The plasma is analysed by HPLC to quantitate 7 hydroxycoumarin (total after deconjugation with beta glucuronidase incubation). High analytical sensitivity is required in order to use 5.0 mg of coumarin. When such sensitivity is not available, the dose of coumarin may be increased up to 50 mg.

HPLC analysis of 7-hydroxycoumarin in urine and plasma:40 **(1) Sample preparation:**

[0121] Urine or plasma samples (0.5 ml) are hydrolyzed with 0.2 ml of β -glucuronidase acetate buffer solution (15 mg/ml acetate buffer, 0.2 M, pH 5.0) at 37°C for 30 min. Extraction is followed with 2 ml ether by vortex for 5 min and centrifuged at 3000 rpm for 10 min. Ether extract (1.2 ml) is transferred to another clean tube and dried down under nitrogen gas. The residue is reconstituted in the HPLC mobile phase (see below), and injected onto HPLC.

(2) HPLC analysis:

50 [0122] The HPLC system consists of Hewlett Packard 1050 HPLC system (pump, autosampler and UV detector) and HP3396II integrator. The chromatographic separation was performed with an HP Spherisorb-ODS2 column (125 x 4 mm I.D., 5 μ m). Samples were eluted with a mobile phase of acetonitrile : water : acetic acid of 150:850:2 (v/v/v) at a flow rate of 1.0 ml/min, and monitored by a UV detector at a wavelength of 324 nm for 7-hydroxycoumarin and 280 nm for coumarin. Samples are quantitatively determined by an external standard method.

[0123] The CYP2A6 activity is expressed as the concentration of 7 hydroxy-coumarin in the plasma at various points in time (e.g. 20, 30, 45 and 75 minutes) or as the ratio of coumarin / 7 hydroxy-coumarin in the plasma at that time.

55 [0124] The preferred mode of use is a simple plasma sample at 20 or 30 minutes after the oral administration of coumarin in which both coumarin and 7-hydroxycoumarin are quantified and in which the coumarin to 7-hydroxycoumarin ration is used as the index of CYP2A6 activity.

Results:

[0125] Blank urine or plasma samples showed no interfering peak for 7-hydroxycoumarin or coumarin. Sensitivity of this method is 1 ng/ml urine or plasma. Intraday and inter-day variations are less than 10%. This analysis is linear from 1 ng to 4000 ng/ml.

[0126] Figure 4 is a graph showing a time course of total 7-hydroxycoumarin concentration detected in the plasma of subjects given coumarin. Figure 4 illustrates various time courses based on corresponding genotypes for CYP2A6.

B. CYP2A6 Genotyping Test

[0127] As for the CYP2A6 genotyping test, mutant alleles which decrease CYP2A6 activity in an individual can be screened in a DNA sample using the materials and screening method described in Example 1.

EXAMPLE 3

In Vivo Phenotype Assay

[0128] The plasma kinetics of nicotine and coumarin were compared after oral administration in 10 smokers and 9 non-smokers (12 males, 7 females) of known CYP2A6 genotype. The dose of nicotine was 4.0 mg (expressed as base) and the dose of coumarin was 50 mg. The plasma concentration of nicotine, cotinine, coumarin and 7-OH-coumarin were measured as described above.

[0129] Optimal separation of $*1/*1$ (wild type homozygotes, $n = 13$) and heterozygotes ($*1/*2$; $*1/*3$, $n = 4$) and homozygotes ($*2/*2$, $n = 2$) was found at 45 min with coumarin by measuring its metabolite 7-OH-coumarin (7-OH-coumarin [μM] $*1/*1 = 5.6 \pm 2.9$; $*1/*2$ or $*1/*3 = 3.8 \pm 1.1$, $p = 0.04$). Optimal separation was found at 90 min with nicotine (nicotine [nM] $*1/*1 = 24 \pm 15$; $*1/*2$ or $*1/*3 = 29 \pm 12$; $*2/*2 = 52 \pm 3$; $*2/*2$ vs. $*1/*2$ or $*1/*3$, $p = 0.01$; $*2/*2$ vs. $*1/*1$, $p = 0.0001$). The use of the coumarin/7-OH-coumarin or nicotine/cotinine ratio did not improve separation.

[0130] Cotinine (nicotine metabolite) was significantly more slowly produced in $*1/*2$ or $*1/*3$ initially, but late in sampling cotinine was actually higher in $*1/*2$ or $*1/*3$, suggesting a role for CYP2A6 in cotinine metabolism. The slope of the curve for appearance vs. time was significantly less for 7-OH-coumarin and greater for nicotine in $*1/*2$ or $*1/*3$ compared to $*1/*1$, as were the areas under the curves, indicating differences in bioavailability, rates of absorption and metabolism. The area of the curves for 7-OH-coumarin and for nicotine were inversely correlated ($p = 0.08$ (Spearman rank), $n = 18$). One $*1/*1$ individual with 4-fold greater 7-OH-coumarin production and one $*2/*2$ individual with high coumarin and low nicotine metabolism were identified, suggesting that CYP2A6 gene variants not detected with current PCR procedures exist.

[0131] These data indicate CYP2A6 genotype is an important determinant of time course for nicotine disposition *in vivo*. These data also indicate that an *in vivo* assay of CYP2A6 reflects the phenotype of the individual, and that the phenotypic determination provides information on the genotype of that individual.

EXAMPLE 4

Tissue Localization of CYP2A6 Expression

[0132] It was determined if the CYP2A6 enzyme was expressed in tissues in which tobacco-related cancers occur (e.g., lung and bladder). In order to determine whether CYP2A6 was expressed in tissues which were subject to tobacco-related cancers, the tissue distribution of the CYP2A6 mRNA was examined in various human tissues using Northern blot analysis. Briefly mRNA from numerous tissues was loaded onto gels and separated by electrophoresis. The mRNA was then transferred to membranes and probed with radioactive CYP2A6 cDNA probe. Evidence was found for the expression of CYP2A6 in uterus, ovaries, colon, small intestine, testis, bladder, heart, stomach, prostate, skeletal muscle, pancreas and lung. These data suggest that in addition to the possibility that CYP2A6-activated carcinogens from the liver might cause cancer in various tissues there could also be *in situ* activation of the procarcinogens in a number of human tissues.

EXAMPLE 5

Epidemiologic Study for Cancer Risk

[0133] In addition to the role that null CYP2A6 alleles have in reducing the rate of nicotine-dependence and the amount smoked if one becomes dependent, procarcinogens found in tobacco-smoke can be activated by CYP2A6. In order to

determine whether there was a significant contribution to cancer rates due to activation of procarcinogens by CYP2A6, independent of its role in smoking, a study was made of individuals with a tobacco-related cancer who were non-smokers. These individuals were passively exposed to tobacco smoke procarcinogens, therefore providing a group in which the role of the CYP2A6 null alleles in the activation of procarcinogens could be tested independently of the role of this enzyme on smoking behaviour. It was found that 14.3% of non-smokers who had bladder cancer (a tobacco-related cancer) carried a null allele for CYP2A6. In contrast, in the control population who were non-smokers and did not have bladder cancer, the frequency of null allele carriers was 24.1%. This demonstrates that individuals who carry null alleles for CYP2A6 are less likely to get a tobacco-related cancer due to their decreased activation of procarcinogens to cancer-causing carcinogens.

EXAMPLE 6

Effect of Methoxsalen, a CYP2A6 Inhibitor on Activation of NNK a Procarcinogen, to its Metabolites NNAL and NNAL Glucuronide

[0134] The effect of methoxsalen; CYP2A6 inhibitor, on nicotine metabolism and NNAL production was studied in eleven (n= 6 females, 5 males) tobacco dependent smokers. Subjects were recruited only if they smoked at least 15 cigarette per day, and were required to smoke the same number of cigarettes each day, on all four study days. During assessment, blood was taken to be analyzed for plasma nicotine and cotinine levels, as well as for CYP2A6 genotyping. Breath carbon monoxide was also measured.

[0135] The four test days were broken down into one placebo day (no drug given) (day 1) and three methoxsalen (10 mg t.i.d. p.o.) treatment days 2, 3, 4), such that medication was taken at 8:00 a.m., 3:00 p.m. and 10:00 p.m. each day. During each study day a smoking log was completed. This log asked subjects to document the number of cigarette smoked from 8:00 a.m. to 3:00 p.m. to 10:00 p.m., and 10:00 p.m. to 8:00 a.m. Study days 1 and 2 could be separated, but days 2, 3 and 4 were required to be consecutive.

[0136] On both study days 1 (placebo) and 4 (treatment), a 24 h urine collection was initiated on waking. At 2:00 p.m. blood was drawn for nicotine and cotinine analysis and breath carbon monoxide was measured. On day 4, a second blood sample was taken for methoxsalen analysis. Urine samples can be analyzed for 24 h NNAL, NNAL glucuronide, creatinine and cotinine.

[0137] Methoxsalen increased plasma nicotine by 17% (23.0 to 27 ng/ml); decreased breath CO by 11% (22.5 to 20.5 ppm) and increased the ratio of plasma nicotine to breath CO (an index of tobacco smoke exposure) by 30% (1.1 to 1.43, $p = 0.033$). The larger decrease in the index of smoke exposure indicates: 1) the smokers decreased the intensity of their smoking due to inhibition of CYP2A6 and slowed nicotine elimination despite being told to not change their smoking; 2) methoxsalen in these doses is an effective inhibitor of CYP2A6; and 3) methoxsalen and other CYP2A6 inhibitors will decrease production of NNAL or related substances and the activation of other carcinogens *in vivo*.

EXAMPLE 7

Influence of the CYP2A6 null alleles on tobacco-smoke exposure leading to lung cancer

[0138] The effect of the CYP2A6 null alleles on activation of procarcinogens was examined in an epidemiological study of lung cancer. The allele frequencies in DNA samples from 227 individuals with lung cancer was determined. Following diagnosis of lung cancer and resection of the tumor and surrounding lung tissue, the DNA was extracted and genotyped for CYP2A6. The population was principally smokers or ex-smokers. Among those from whom detailed smoking histories were available, we were able to assess the number of pack-years of smoking (20 cigarettes/day for one year = one pack-year) as a measure of procarcinogen exposure, prior to detection of the lung cancer. Those individuals who had wt/wt CYP2A6 activity required an average of only 45 pack-years prior to lung cancer detection. In contrast, those individuals with a CYP2A6 null allele, who activate less of the procarcinogens, required considerably more procarcinogen exposure prior to detection of lung cancer (e.g., 54 pack-years). Thus those individuals with decreased CYP2A6 activity activate less of the tobacco-smoke procarcinogens and require greater exposure before lung cancer is detected.

[0139] It was also observed that the number of individuals with the CYP2A6V1 allele in the lung cancer population was decreased relative to a non-lung cancer control population, consistent with the relative protection against cancer offered by decreased procarcinogen activation. This was observed in both non-smokers and smokers with lung cancer relative to their respective controls.

[0140] In addition, all of the individuals who had *ras* oncogene mutations in the tumor tissues were full activity CYP2A6 wildtype indicating a decreased risk for oncogene mutations in those individuals with decreased CYP2A6 activity (e.g., carriers of the CYP2A6 null alleles). *Ras* oncogene mutations are predictive of a poorer treatment outcome and faster

growing tumors relative to those tumors without ras oncogene mutations. This suggests that individuals with CYP2A6 null alleles, were less likely to have mutated ras oncogenes, and were more likely to have a better treatment prognosis.

[0141] These data indicate the utility in assessing CYP2A6 alleles for estimation of cancer risk (null alleles being associated with decreased risk for lung cancer) and that inhibition of CYP2A6 will decrease procarcinogen activation decreasing the risk for cancer.

EXAMPLE 8

Effect of CYP2A6 Inhibition on the Bioavailability of Oral Nicotine

[0142] An *in vivo* study was undertaken to determine the effect of CYP2A6 inhibition on the bioavailability of oral nicotine. In particular, the study compared the kinetic effects of nicotine cotreatment with methoxsalen 30 mg, tranlycypromine 10 mg and of placebo (i.e., nicotine only) p.o. on the bioavailability of nicotine 4 mg p.o. (expressed as base; nicotine bitartrate salt was actually administered), and the acute safety and acceptability of the three cotreatments. Additionally, preliminary information was obtained about effects on nicotine craving following these cotreatments.

[0143] The subjects for the study were smokers following a specified abstinence regimen as set out below. There were 12 subjects.

[0144] The smokers underwent placebo p.o. and two separate cotreatments 30 (methoxsalen 30 mg and tranlycypromine 10 mg) accompanying nicotine 4 mg p.o. During a 4-hour test session, blood and urine samples were collected for kinetic measures, and physiologic and subjective measures were collected. The treatment order was randomized and counterbalanced and the drug presentations were single-blind, namely, the subjects were unaware of what drug they were taking.

[0145] All of the subjects had the following characteristics:

- (a) age at least 21;
- (b) current consumption of at least 25 cigarettes per day;
- (c) DSM IV current tobacco dependence;
- (d) nicotine dependence as indicated by a score of at least 3 on the Fagerström Test of Nicotine Dependence (FTND);
- (e) no regular use of tobacco in any form other than cigarettes;
- (f) ability to abstain from cigarette smoking and from caffeine for up to 12 hours;
- (g) agreement and ability to maintain the use of any therapeutic drugs on a consistent schedule across the study days.

All of the subjects did not have any of the following characteristics:

- (a) known sensitivity to methoxsalen or chemically similar compounds;
- (b) known excessive photosensitivity;
- (c) current use of any antidepressants, sympathomimetics, CNS depressants, hypotensive agents, or antiparkinsonian drugs (because of possible adverse tranlycypromine interactions);
- (d) body weight < 51 kg (30 mg methoxsalen is not recommended for use below this body weight);
- (e) pregnancy or lactation;
- (f) risk of pregnancy (females who are sexually active with male partners and not using highly effective contraceptive precautions, defined as surgical sterilization of either partner, oral contraceptives, barrier and spermicide, or condom and spermicide);
- (g) liver damage, blood dyscrasias (counterindications for tranlycypromine);
- (h) symptoms suggestive of cardiac disease or hypertension;
- (i) any other medical or psychiatric condition that requires further investigation or treatment or that is a contraindication for any of the proposed study drugs;
- (j) current desire or attempts to quit smoking within the expected duration of the study series; and
- (k) any other condition likely to interfere with compliance with the study schedule or successful collection of study measures.

[0146] There were two separate study schedules for subjects tested in the morning and in the afternoon. On both schedules, each subject abstained from tobacco, food, beverages (i.e., other than water), and any inconsistently used drugs from midnight before each study day but continued to take any regularly scheduled drugs allowed by the protocol (e.g., oral contraceptives, daily vitamins).

[0147] Subjects on the morning schedule continued such abstinence until arrival at the test site at approximately 8 am. Subjects on the afternoon schedule ate a normal-sized breakfast, including at most one cup of a caffeinated beverage and one cigarette before 9 am. From 9 am then to approximately 1 pm subjects in the afternoon session resumed the

EP 1 033 979 B2

abstinence regimen until arrival at the test site.

[0148] Before baseline measures were taken, a breath CO sample (Ecolyzer) was taken to assess compliance with the smoking abstinence (< 10 ppm expected). The subsequent daily schedule is set out in Table 3. All measurements were with respect to a time zero at 9:00 am or 2:00 pm, at which time a nicotine capsule and a cotreatment are taken p.o. Each SMS cycle consisted of heart rate, blood pressure, and subjective measures. A standard breakfast or lunch (but without caffeine) was served after the blood sample at + 1:00 h.

Table 3

Time Elapsed	Event
-00:45	Prepare the subject
-00:30	Blood sample (8 mL) taken - #1
-00:15	SMS cycle #1
00:00	All capsules p.o.
00:30	Blood sample (8 mL) taken - #2
00:50	SMS cycle #2
01:00	Blood sample (8 mL) taken - #3
01:30	Blood sample (8 mL) taken - #4
01:50	SMS cycle #3
02:00	Blood sample (8 mL) taken - #5
2:50	SMS cycle #4
03:00	Blood sample (8 mL) taken - #6

[0149] Subjects were medically assessed for discharge no earlier than +2:00 h and were discharged after all measures were complete at +3:00 h. Subjects were not allowed to smoke until after their discharge. The schedule was in certain circumstances delayed by up to 20 minutes, consistent across the four days, in order to allow three subjects to be tested on the same day.

[0150] Each subject was tested on two non-consecutive days in a week for three separate weeks and maintained a morning or afternoon schedule consistently.

[0151] Sterile nicotine bitartrates was obtained by the Pharma Centre from Sigma Chemical. The reported purity was > 99.5 % which was confirmed by HPLC. The nicotine bitartrate powder was measured on a precision balance accurate to within 1 µg, measured into portions containing 4 mg of the nicotine base, and then encapsulated. Capsules were filled to a tolerance of +2% of their nominal mass of nicotine powder.

[0152] Methoxsalen is marketed in Canada in two forms, one of relatively low bioavailability (trade name OxSORALEN®) and two of approximately twice as high a bioavailability (OxSORALEN-ULTRA® and Ultra MOP®). The package insert for Ultra MOP® (Canderm Pharmacal Ltd.) recommends a daily dose of 30 mg to 50 mg for any patient weighing 51 kg or more. Subjects were restricted to a minimum body weight of 51 kg, in order to allow the use of a fixed 30 mg dose for all subjects; the dose was not adjusted for larger subjects.

[0153] Capsules of methoxsalen 10 mg and tablets of tranylcypromine 10 mg (Pamate®) were used in their marketed forms. Because it was a randomized but single-blind study, subjects were able to recognize that the capsule forms and number varied from day to day, but they did not know which form represented which drug.

[0154] Lactose tablets were used for the placebo.

[0155] For the first four days, each day's drug supply consisted of one or three capsules, as set out in Table 4, in addition to nicotine 4 mg. The investigators were unaware of the distribution to preserve random allocation.

[0156] The nicotine and other capsules were taken simultaneously.

[0157] A separate, printed, reference copy of each subject's treatment randomization code was provided to the investigators after the drugs were dispensed.

Table 4

Active Drug, Capsule Form	Administered Dosage
placebo	1 x coumarin-size placebo

EP 1 033 979 B2

(continued)

Active Drug, Capsule Form	Administered Dosage
methoxsalen, 30 mg	3 x methoxsalen, 10 mg
tranlycypromine, 10 mg	1 x tranlycypromine, 10 mg

5 [0158] Using an indwelling venous catheter, 8 mL blood samples were collected at the elapsed times set out in Table 3. These samples were analyzed for nicotine, cotinine and inhibitor concentration.

10 [0159] Two separate urine samples were collected, a baseline just prior to the capsules and a three-hour pooled sample. Each urine sample was analyzed for nicotine and cotinine content.

15 [0160] Plasma and urinary nicotine and cotinine (and also the conjugates in urine) were determined using an HPLC method with a UV detector. Specifically, 1 mL of sample, 50 μ L (2 μ g/mL) of the internal standard (N-ethylnornicotine) and 1 mL of trichloroacetic acid (10%) were pipetted into each tube (12 mL). The tube was capped, vortex-mixed for a few seconds, and then centrifuged at 30,000g for 5 minutes. The clear supernatant was decanted in a second tube. To this protein-free plasma extract was added 0.5 mL of a 5 M potassium hydroxide solution and 6 mL of methylene chloride. The second tube was then capped, agitated for 30 minutes in a horizontal shaker and then centrifuged to separate the phases. The aqueous phase (the top layer) was aspirated, and 3.0 mL of 0.5 N hydrochloric acid solution was added to the organic phase and vortex-mixed for 30 seconds. The phases were separated by centrifugation, and the aqueous phase was transferred to a clean tube with 0.5 mL of 5 M potassium hydroxide solution, followed by addition of 5 mL of methylene chloride and vortex mixing for 30 seconds. The phases were separated by centrifugation, the aqueous (top) layer was aspirated, and 200 μ L methanolic hydrochloric acid (10 mmol HCl in methanol) was added to the remaining solution and mixed gently. The organic solvent was then evaporated under nitrogen in a water bath at 40°C. The sides of the tube were washed with 200 μ L of methanolic hydrochloric acid and the solution was evaporated. The residue was reconstituted in 100 μ L of 30% methanol and 90 μ L thereof was injected in the HPLC column.

20 [0161] The chromatographic separation was performed with a Supelco™ 5-8347 LC-8-DB (150 x 4.6 mm, 5 μ m). The sample was eluted with a mobile phase of 0.34 M citric acid buffer : acetonitrile, 800 : 45 (v/v) containing 0.34 M KH_2PO_4 , 1-heptane sulphonate (671 mg) and triethylamine (5 mL) with a flow rate of 1.3 mL/min, and monitored by a UV detector at $\lambda = 260$ nm.

25 [0162] The sensitivity of the nicotine assay is < 1 ng/mL and that of the cotinine is < 5 ng/mL. Conjugates in urine were determined after hydrolysis with β -glucuronidase, when appropriate.

30 [0163] Plasma nicotine concentration was determined using the above-mentioned assay, and the results are illustrated in Figure 7 as the mean for all subjects.

35 [0164] Cardiovascular measures, transduced by a Hewlett/Packard 78352C Adult Patient Monitor and recorded directly into a computer included heart rate and blood pressure (while seated).

[0165] Using a visual analog scale, each subject was asked to evaluate, on a scale of 0 to 100, his/her current desire to smoke a various points in time, both pre- and post drug administration (Appendix A).

[0166] For the purposes of establishing clinical kinetic differences and describing kinetic parameters, the primary dependent variable was the 3-hour trapezoidal-rule nicotine AUC.

40 [0167] Figure 7 illustrates the mean plasma nicotine concentrations measured just prior to oral drug administration and for three hours thereafter (during which no smoking was allowed). As illustrated, the combined methoxsalen/nicotine and tranlycypromine/nicotine treatments both induce an increase in mean plasma nicotine concentration that is at least four times as large as that induced by the placebo/nicotine combination.

45 [0168] Figure 8 illustrates the self-rated "Current desire to smoke" evaluation, using a visual analog scale scored from 0 to 100. As illustrated, both the methoxsalen/nicotine and tranlycypromine/nicotine combination reduced the desire to smoke significantly more than does the placebo/nicotine combination.

EXAMPLE 9

Effects of Metabolically Enhanced Oral Nicotine Replacement Therapy on Short-term Smoking Behaviour

50 [0169] A study was undertaken to determine the effects of metabolically enhanced oral nicotine replacement therapy on short-term smoking behaviour.

55 [0170] Because nicotine is the addictive agent in tobacco dependence, and smokers regulate their brain nicotine within a fairly narrow individual concentration band, any effective non-smoking method of nicotine delivery should result in a decrease in smoking by allowing smokers to maintain plasma nicotine without resorting to smoking and, in some cases, reduce the secondary reinforcement of smoking behaviour as a component of eventual smoking cessation. This effectiveness can only be enhanced if the mechanism for ensuring effective delivery also delays the clearance of plasma

EP 1 033 979 B2

nicotine after the absorption stage. A model for testing the acute behavioural effects of this treatment strategy is provided in a previous study of the effectiveness of nicotine gum (Nemeth-Coslett R, et al., "Nicotine gum: dose-related effects on cigarette smoking and subjective ratings," *Psychopharmacology*, 92(4):424-30 (1987)), where smoking in a 90-minute test period was significantly affected by the nicotine content of the gum.

5 **[0171]** In this Example, all four combinations of placebo/methoxsalen and placebo/nicotine were tested (i.e., (i) placebo methoxsalen and nicotine; (ii) methoxsalen and nicotine, (iii) methoxsalen and placebo nicotine; and (iv) placebo methoxsalen and placebo nicotine).

[0172] This Example demonstrates: the kinetic effectiveness of methoxsalen-enhanced oral nicotine replacement therapy in briefly abstinent smokers; and the behavioural effectiveness of methoxsalen-enhanced oral nicotine replacement therapy in briefly abstinent smokers.

10 **[0173]** There were 11 subjects. The subject inclusion and exclusion criteria used in Example 8 were used in this Example.

[0174] The subjects each underwent four separate sessions of 90 minutes smoking abstinence followed by 90 minutes ad lib smoking, where the following four treatments were each presented double-blind once during the first four study days, in randomized, counterbalanced order, during the abstinence period: (i) placebo methoxsalen with placebo nicotine, (ii) placebo methoxsalen with 4 mg nicotine, (iii) methoxsalen 30 mg with placebo nicotine, and (iv) methoxsalen 30 mg with 4 mg nicotine. Methoxsalen 10 mg capsules were used, as in Example 1, and capsules of royal jelly were used as the placebo. Capsules were dispensed in an opaque vial, and neither subjects nor investigators viewed the capsules prior to the subjects placing them directly into their mouths.

15 **[0175]** Nicotine 4 mg capsules were prepared as in Example 8, and corresponding royal jelly capsule placebos containing only lactose were also prepared. Subjects took the three methoxsalen/placebo capsules and one nicotine/placebo capsule either all at once or consecutively.

[0176] The treatment order was counterbalanced across the two sexes and the two times of day to the extent possible. The order of the treatments was determined by a computerized randomization program. The treatment was double-blind.

25 **[0177]** As in Example 8, there was a morning and afternoon schedule.

[0178] Study sessions were scheduled twice each day, with three subjects running simultaneously, beginning at 8:30/8:40/8:50 am and at 1:00/1:10/1:20 pm. Sessions lasted for about 4 hours. Prior to each session, subjects were allowed to smoke, eat, and drink caffeine as they desired up to 90 minutes before each session, at which time they stopped eating and drinking (other than water). Each session began 60 minutes before a drug/placebo/nicotine were taken. The precise schedule is set out in Table 5.

Table 5

Time Elapsed	Event
-00:40	Pre-abstinence cigarette
-00:30	Abstinence begins
-00:10	1. Blood sample (8 mL) taken - #1 2. CO measured 3. Questions 1-9 in Appendix C
00:00	1. CO measured 2. All capsules p.o.
00:50	1. Blood sample (8 mL) taken - #2 2. CO measured 3. Questions 1-12 in Appendix C
00:59	1. CO measured 2. Video camera on
01:00	1. Abstinence ends 2. Free smoking begins
02:30	1. Video camera off 2. Free smoking ends 3. Blood sample (8 mL) taken - #3 4. CO measured 5. Questions 1-17 in Appendix C

(continued)

<u>Time Elapsed</u>	<u>Event</u>
	6. Abstinence resumes
02:40	CO measured
02:50	CO measured
03:00	CO measured

[0179] The first post-cigarette abstinence period lasted 90 minutes, of which the last 60 minutes were post administration of placebo/drug/nicotine. The second abstinence period was included to facilitate repeated measures of the post-smoking breath carbon monoxide (CO). On the three occasions when blood samples were collected, the subject also answered a brief questionnaire about possible study drug symptoms and effects and about desire to smoke. Additionally, on the third occasion, there were also questions about perception of the cigarettes smoked during the free smoking period. This questionnaire (see Appendix A) is based on the one used in the nicotine gum study (Nemeth-Coslett, et al. (1987)).

[0180] During the free smoking period, subjects were allowed to smoke as they wished, providing only that they stay within the area of the room visible to the video camera, and to eat light snacks and drink non-caffeinated beverages.

[0181] The primary dependent variable measured was the change in breath CO during the free-smoking period, measured as the mean of the three samples 10, 20, and 30 minutes post-smoking minus the mean of the two samples 10 and 0 minutes pre-smoking. Other dependent variables measured were the change in plasma nicotine between 0 and 150 minutes post-drug, the responses to the symptom and rating scales, the consumption of tobacco in the free smoking period (measured as the weight of butts remaining subtracted from the weight of the same number of unsmoked cigarettes), and the puff timing and count from analysis of the videotapes.

[0182] Dependent variables were evaluated in an analysis of variance, with the treatment drug combinations as the primary independent variable of interest, with sex, morning/afternoon schedule, and treatment order as additional explanatory variables removed from the error term.

[0183] The results of the study of Example 10 will now be discussed with reference to Figures 9-14.

[0184] Figure 9 illustrates the mean breath carbon monoxide concentration measured just prior to oral drug administration, 60 minutes later (no smoking allowed) and after the 90 minute free smoking period. As illustrated, the combined methoxsalen/nicotine treatment results in a significant and large reduction in the increased in breath carbon monoxide during the smoking phase. The carbon monoxide levels increased in the combined methoxsalen/nicotine treatment group only 30% of that seen in the other conditions, reflecting a large reduction in smoking and smoke exposure. This reduction may be attributable due to any combination of fewer puffs, shallower puffs and/or puffs held for a shorter duration before exhalation.

[0185] Figure 10 illustrates the ratio of the increased plasma nicotine concentration to increased breath carbon monoxide concentration over the 90 minute free smoking period. In other words, this Figure illustrates the measure of potential reduction in smoke exposure that might occur while dependent smokers replenish their systemic plasma nicotine content. As illustrated, the methoxsalen/nicotine treatment stands apart from all three of the other treatments and from their mean, more than doubling the gain in nicotine per unit of increase in breath carbon monoxide concentration.

[0186] Figure 11 illustrates the commonly used measure of smoking: the mean number of cigarettes smoked during the 90 minute period. As illustrated, the combined methoxsalen/nicotine treatment is associated with the least smoking, however number of cigarettes consumed is an insensitive measure of smoke exposure and smoking behaviour compared to breath carbon monoxide concentration.

[0187] Figure 12 illustrates the mean cumulative number of puffs taken by the end of each 10 minute period during the 90 minute free smoking period, and the data is summarized by the area under this curve. This area would increase if either the total number of puffs increased, or if the same number were consumed earlier thereby shifting the curve to the left. As illustrated, the methoxsalen/nicotine treatment is associated with the fewest cumulative number of cigarette puffs.

[0188] Figure 13 illustrates that the number of grams of tobacco burned is significantly less in the methoxsalen/nicotine treatment group. Again, this measure is less sensitive than direct measures of smoking behaviour and smoke exposure (e.g., breath carbon monoxide concentration and nicotine/breath carbon monoxide concentration).

[0189] Figure 14 illustrates that the inhibition of CYP2A6 metabolism of nicotine achieves the reduction in breath carbon monoxide by changing nicotine-regulated smoking behaviour. The latency between cigarettes is significantly prolonged by the combined methoxsalen/nicotine treatment.

[0190] In summary, the results illustrated in Figures 9-14 show a modification in smoking behaviour by subjects who were treated with a combination of methoxsalen and nicotine. Specifically, key objective indicators such as plasma

nicotine concentration and breath carbon monoxide were significantly reduced compared to the other treatment regimens.

[0191] CYP2A6 metabolizes approximately 75% of nicotine *in vivo*. Tobacco-dependent smokers regulate their smoking to maintain nicotine levels; CYP2A6 inhibition should decrease nicotine metabolism, decrease smoking and smoke exposure (e.g. breath CO). Overnight nicotine-abstinent dependent smokers (6 males, 5 females) smoked one cigarette followed by one of four oral drug combinations in crossover counter-balanced order: methoxsalen 30 mg (CYP2A6 inhibitor $K_i = 0.2 \mu\text{M}$) or placebo with either nicotine 4.0 mg or placebo. Sixty minutes later, subjects started 90 mins of *ad libitum* smoking. Subjects receiving methoxsalen with oral nicotine smoked less than in the placebo/placebo (e.g. breath CO 50% less increase; latency to the second cigarette 83% increase, number of cigarettes smoked 24% decrease; tobacco burned (grams) 24% decrease, total number of puffs taken decrease 25% [all $p < 0.05$]). In addition, on several measures (e.g. latency to second cigarette) the rank order of response was methoxsalen/nicotine > methoxsalen/placebo > placebo/nicotine > placebo/placebo suggesting a methoxsalen effect on systemic clearance of nicotine. CYP2A6 inhibition alone or combined with oral nicotine decreases smoking and could have a role in tobacco smoking cessation, exposure reduction or relapse prevention strategies.

EXAMPLE 10

Inhibitors Of Nicotine's Metabolism: potential New Treatments For Tobacco Dependence

[0192] Nicotine is inactivated by CYP2A6 to cotinine. As nicotine bioavailability is low (20-35%), an oral nicotine replacement is feasible. *In vitro* inhibition of nicotine metabolism was studied in expressed CYP2A6 using tranlycypromine, methoxsalen, and as inhibitors ($K_i = 0.05\text{-}6 \mu\text{M}$). In dependent smokers methoxsalen, 30-50 mg orally 30 min prior to nicotine 31 $\mu\text{g}/\text{kg}$ subcutaneously (3 doses, hourly), increased the 8-hour mean plasma nicotine by 49% ($p < 0.01$) while coumarin (225 mg hourly x 6) increased it by 15% ($p < 0.05$) compared to placebo. Using methodology described above, studies conducted in regular smokers ($n = 7\text{-}12$) given nicotine (4.0 mg p.o.) alone and concurrently with placebo, methoxsalen (3 mg, 10 mg or 30 mg) or tranlycypromine (2.5 mg or 10 mg) significantly increased the plasma nicotine compared to placebo (see Figure 15). Specifically, methoxsalen 10 and 30 mg (M10 and M30, Figure 15) and tranlycypromine 2.5 and 10 mg (T2.5 and T10, Figure 15) produced approximate 100% increases in plasma nicotine ($p < 0.01$). In addition, these increases in oral nicotine bioavailability were associated with a significant ($p < 0.05$) decrease in desire to smoke for M10 and M30 and T2.5 ($p = 0.17$) (see Figure 15, solid circles).

[0193] From these studies it is evident that methoxsalen and tranlycypromine in doses 1/4 and 1/8, respectively, of their current therapeutic doses used for treating psoriasis and depression, respectively, can be used to inhibit nicotine first-pass metabolism and systemic metabolism. Other CYP2A6 inhibitors and their isomeric forms can be expected to do the same.

EXAMPLE 11

Extraction of Hypericum

[0194] The following procedures were used to prepare an extract of *Hypericum perforatum*:

[0195] An extraction mixture of 10 Hypericum capsules (0.3% hypericin) and 50 ml of 80% methanol (water 20%, v/v) was placed in a beaker (125ml). In one protocol the extraction was carried out using cold methanol. In a second protocol, the extraction mixture was placed in a water-bath and heated until boiling (about 80°C). The mixture was kept boiling for 30 min, keeping the volume to 50 ml by adding methanol, then cooled down at room temperature, and centrifuged at 3,000g for 5 min. The resulting extract was then blown to dryness and resuspended in trisbuffer pH 7.4.

EXAMPLE 12

Effect of Hypericum Extracts on CYP2A6 Activity

[0196] Nicotine metabolism was monitored *in vitro*. Inhibitor assessment was carried out by comparing the assay including 50 μl tris buffer with the extracts prepared in Example 11 (50 μl , diluted in tris buffer). Human liver microsomes or CYP2A6 microsomes were used. The concentration of inhibitor in Hypericum was calculated on the basis of an apparent molecular weight of the inhibitor of 504 and a concentration of 0.3% active material in the plant material when diluting to yield concentrations of 20, 10, 5, 1, 0.1 and 0.01 and 0.01 μM .

Incubation mixture:

[0197]

EP 1 033 979 B2

Substrate 80 μ M (50 μ l tris buffer)
NADPH1 mM (50 μ l tris buffer)
Microsomes 80 μ g (30 μ l tris buffer)
Cytosol (rat) 20 μ l (tris buffer)
Tris buffer 50 μ l (pH7.4)

Final volume 200 μ l

5

10

Incubation Procedure:

15

[0198] The incubation was carried out at 37°C for 30 min. An internal standard (50 μ l, caffeine, 0.05 mg/ml) was added to the incubation mixture, followed by DCM (1ml). The mixture was shaken for 10 min and centrifuged for 5 min at 3,000 g. The top layer was aspirated. HCl (0.01 N, 100 μ l) was added, followed by shaking for 1 min, then centrifuge for 5 min at 3,000 g. 30 μ l of the HCl layer was injected for HPLC.

HPLC Conditions

20

[0199]

25

Column: Supelco; 5-8347; LC-8-DB; 150 x 4.6 mm; 5 μ m
 λ : 260 nm
Flow rate: 1.3 ml/min
Mobile phase: 1000/120 (citric buffer/acetonitrile, v/v)
Citric buffer: Citric Acid 7.14g (0.34 M)
KH₂PO₄ 4.627g (0.34 M)
1-Heptane sulphonate 670mg
Triethylamine 5 ml

Final volume 1000 ml
Adjust the pH to 4.40 with 5 N KOH

30

35

Retention times (min):

[0200]

40

2.2 (nicotine iminium ion)
2.7 (nicotine)
3.4 (continine)
3.9 (caffeine) (internal standard)

45

[0201] Figure 16 demonstrates the inhibition of nicotine metabolism with (1) cold methanol extract of Hypericum; (2) a hot methanol extract of Hypericum; (3) purified Hypericin; and (4) a negative control. The results indicate that both methanol extracts of Hypericum can inhibit CYP2A6 activity.

EXAMPLE 13

50

Effect of St. John' Wort on Nicotine Metabolism

[0202] Twelve subjects received placebo or 3 St. John's Wort capsules 300mg plus oral nicotine 4.0 mg as base orally. Blood samples were taken at designated times over 3 hours.

55

[0203] The results shown in Figures 18 and 19 demonstrate that St. John's Wort increases the bioavailability of nicotine *in vivo*. The mean plasma nicotine concentrations were 64% higher after St. John's Wort.

EXAMPLE 14

Effect of Esculetin on CYP2A6 Activity

5 **[0204]** Esculetin, a compound found in *Cichorium intybus* and *Bougainvillea spectabilis*, was tested for its ability to inhibit nicotine metabolism by CYP2A6 using the methods set forth in Example 12.

[0205] The results, shown in Figure 19, demonstrate that esculetin is a potent inhibitor of CYP2A6.

Table 1

	Average Number of Cigarettes Smoked Per Day								
	Genotype Frequency			TD			AT		
	NTD	TD	AT	Males	Females	Total	Males	Females	Total
Age	28.3	31.2	37.8	31.1	31.4	31.2	37.2	41.4	37.8
wt/wt	130	114	62	26.1	19.5	23.2	28.9	27.8	28.7
wt/mut	31	17	7	19.3	18.7	19.1	29.7	50.0	32.6
mut/mut	2	2	1	22.5	-	22.5	25	-	25
n	163	133	70	76	57	133	60	10	70
wt/wt: CYP2A6*1/CYP2A6*1 wt/mut: CYP2A6*1/CYP2A6*2 + CYP2A6*1/CYP2A6*3 mut/mut: CYP2A6*2/CYP2A6*2									

Claims

- 30 1. Use of a CYP2A6 inhibitor to prepare a medicament for use contemporaneously with nicotine in the treatment of a condition requiring regulation of nicotine metabolism in an individual having a CYP2A6 genotype associated with an active form of the CYP2A6 enzyme, said medicament comprising an effective amount of one or more substances which inhibit CYP2A6 activity and which are selected from tranlylcyproamine, esculetin, selegiline or a natural product selected from *Hypericum* or extracts thereof.
- 35 2. The use as claimed in claim 1, wherein said condition is smoking and inhibition of the CYP2A6 enzyme inhibits the conversion of nicotine to cotinine.
3. The use as claimed in 1 or claim 2, wherein the medicament is formulated for oral administration.
- 40 4. The use as claimed in any one of claims 1 to 3, wherein the medicament is formulated in a single composition.
5. The use as claimed in claim 1, wherein tranlylcyproamine is in an amount from 0.1 mg to 80 mg.
- 45 6. The use as claimed in any one of claims 1 to 5, further comprising administering an inhibitor of CYP2B6 to said individual contemporaneously with said one or more substances.
7. The use as claimed in any one of claims 1 to 6, wherein said condition is cancer and inhibition of the CYP2A6 enzyme inhibits the metabolism of a procarcinogen to a carcinogen.
- 50 8. The use as claimed in claim 7, wherein said procarcinogen is a N-nitrosodialkylamine selected from the group consisting N-nitrosodiethylamine, N-nitrodimethylamine, and 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone.
- 55 9. The use as claimed in any one of claims 1 to 8, wherein said condition is selected from (i) addiction to tobacco, (ii) risk of developing an addiction to tobacco, (iii) risk of developing a smoking associated cancer, and (iv) exposure to one or more compounds which are converted to carcinogens by CYP2A6.
10. The use according to any one of claims 1-9 wherein said medicament is formulated as sustained release tablets or

capsules.

- 5
11. A composition comprising (a) nicotine and (b) one or more substances which inhibit CYP2A6 activity and which are selected from tranlylcypromine, esculetin or selegiline for enhancing the effectiveness of an oral nicotine replacement therapy in an individual having a CYP2A6 genotype associated with an active form of the enzyme.
 12. A composition as claimed in 11 , formulated as a controlled or slow release capsule system.

10 **Patentansprüche**

- 15
1. Verwendung eines CYP2A-Inhibitors zur Zubereitung eines Medikamentes zur gleichzeitigen Verwendung mit Nikotin bei der Behandlung eines Zustandes, der eine Regelung des Nikotinstoffwechsels in einem Individuum mit einem CYP2A6-Genotyp, der mit einer aktiven Form des CYP2A6-Enzyms assoziiert ist, erfordert, wobei das Medikament eine wirksame Menge von einer oder mehreren Substanzen umfasst, die CYP2A-Aktivität hemmen, und die ausgewählt sind aus Tranlylcypromin, Esculetin, Selegilin oder einem Naturprodukt ausgewählt aus *Hypericum* oder Extrakten davon.
 - 20
 2. Verwendung nach Anspruch 1, wobei der Zustand Rauchen ist und das Hemmen des CYP2A-Enzyms die Umwandlung von Nikotin zu Cotinin hemmt.
 3. Verwendung nach Anspruch 1 oder Anspruch 2, wobei das Medikament für eine orale Verabreichung formuliert ist.
 - 25
 4. Verwendung nach einem der Ansprüche 1 bis 3, wobei das Medikament in einer Einzelzusammensetzung formuliert ist.
 5. Verwendung nach Anspruch 1, wobei Tranlylcypromin in einer Menge von 0,1 mg bis 80 mg vorliegt.
 - 30
 6. Verwendung nach einem der Ansprüche 1 bis 5, welche ferner das Verabreichen eines Inhibitors von CYP2B6 an das Individuum, gleichzeitig mit der einen oder den mehreren Substanzen umfasst.
 7. Verwendung nach einem der Ansprüche 1 bis 6, wobei der Zustand Krebs ist und die Hemmung des CYP2A-Enzyms den Stoffwechsel eines Procarcinogens zu einem Carcinogen hemmt.
 - 35
 8. Verwendung nach Anspruch 7, wobei das Procarcinogen ein N-Nitrosodialkylamin ist, das aus der Gruppe ausgewählt ist, die aus N-Nitrosodiethylamin, N-Nitrodimethylamin und 4-(Methylnitrosamin)-1-(3-pyridyl)-1-butanon besteht.
 - 40
 9. Verwendung nach einem der Ansprüche 1 bis 8, wobei der Zustand ausgewählt ist aus (i) Tabaksucht, (ii) dem Risiko, eine Tabaksucht zu entwickeln, (iii) dem Risiko eine mit dem Rauchen in Zusammenhang stehende Krebserkrankung zu entwickeln und (iv) der Exposition gegenüber einer oder mehrerer Verbindungen, die durch CYP2A6 in Carcinogene umgewandelt werden.
 - 45
 10. Verwendung nach einem der Ansprüche 1 bis 9, wobei das Medikament als anhaltend freisetzende Tabletten oder Kapseln formuliert wird.
 - 50
 11. Zusammensetzung, welche (a) Nikotin und (b) eine oder mehrere Substanzen, die CYP2A-Aktivität hemmen und ausgewählt sind aus Tranlylcypromin, Esculetin oder Selegilin, umfasst, um die Wirksamkeit einer oralen Nikotiner-satztherapie in einem Individuum mit einem CYP2A6-Genotyp, der mit einer aktiven Form des Enzyms assoziiert ist, zu stärken.
 12. Zusammensetzung nach Anspruch 11, die als kontrolliert oder langsam freisetzendes Kapselsystem formuliert ist.

55 **Revendications**

1. Utilisation d'un inhibiteur du CYP2A pour préparer un médicament destiné à une utilisation en même temps que la nicotine dans le traitement d'un état qui requiert une régulation du métabolisme de la nicotine dans un individu avec


EP 1 033 979 B2

un génotype de CYP2A6 associé avec une forme active de l'enzyme CYP2A6, ledit médicament comprenant une quantité efficace d'une ou plusieurs substances qui inhibent l'activité CYP2A, et que l'on sélectionne parmi la tranlylcypromine, l'esculetine, la selegiline ou produits naturels sélectionnée parmi *Hypericum* ou des extraits de cela.

- 5
2. Utilisation selon la revendication 1, dans laquelle ledit état est le tabagisme et l'inhibition de l'enzyme CYP2A inhibe la conversion de la nicotine en cotinine.
3. Utilisation selon la revendication 1 ou la revendication 2, dans laquelle on formule le médicament en vue d'une administration orale.
- 10
4. Utilisation selon l'une quelconque des revendications 1 à 3, dans laquelle on formule le médicament en une composition unique.
5. Utilisation selon la revendication 1, dans laquelle la tranlylcypromine se trouve en une quantité de 0,1 mg à 80 mg.
- 15
6. Utilisation selon l'une quelconque des revendications 1 à 5, comprenant en outre l'administration d'un inhibiteur du CYP2B6 audit individu en même temps que lesdites une ou plusieurs substances.
7. Utilisation selon l'une quelconque des revendications 1 à 6, dans laquelle ledit état est un cancer et l'inhibition de l'enzyme CYP2A inhibe le métabolisme d'un procancérogène en un cancérogène.
- 20
8. Utilisation selon la revendication 7, dans laquelle ledit procancérogène est une N-nitrosodialkylamine sélectionnée parmi le groupe comprenant la N-nitrosodiéthylamine, la N-nitrodiméthylamine et la 4-(méthylnitrosamine)-1-(3-pyridyl)-1-butanone.
- 25
9. Utilisation selon l'une quelconque des revendications 1 à 8, dans laquelle on sélectionne ledit état parmi (i) une dépendance envers le tabac, (ii) un risque de développer une dépendance envers le tabac, (iii) un risque de développer un cancer associé au tabac, et (iv) une exposition à un ou plusieurs composés qui sont convertis en cancérogènes par le CYP2A6.
- 30
10. Utilisation selon l'une quelconque des revendications 1-9, dans laquelle on formule ledit médicament sous forme des comprimés ou des capsules à libération prolongée.
11. Composition comprenant (a) de la nicotine et (b) une ou plusieurs substances qui inhibent l'activité CYP2A et que l'on sélectionne parmi la tranlylcypromine, l'esculetine, la selegiline, en vue d'augmenter l'efficacité d'un traitement de substitution nicotinique dans un individu avec un génotype de CYP2A6 associé avec une forme active de l'enzyme CYP2A6.
- 35
12. Composition selon la revendication 11, que l'on formule sous forme d'un système de capsule à libération contrôlée ou libération lentement.
- 40
- 45
- 50
- 55

FIGURE 1

Heterozygous CYP2A6 individuals have lower CYP2A6 activity than wild type/wild type (wt) individuals



Application of a method to characterize CYP2A6 activity in human subjects by taking plasma samples at times as early as 35 minutes after administration of an oral dose of coumarin (100 mg in this example). Lower doses of coumarin may also be used and the data can also be expressed as a ratio of coumarin/7-OH coumarin. The test can also be performed using oral nicotine or another CYP2A6 substrate.

FIGURE 2A (for the purpose of illustration)







FIGURE 2B (for the purpose of illustration)




Pilocarpine




Nicotine



4,4'-Methylene bis[2-chloroaniline]




6-Aminochrysene



α -Naphthoflavone



naringenin



naringin

FIGURE 2C (for the purpose of illustration)










FIGURE 2D (partly for the purpose of illustration)


Non-selective MAO inhibitors



Selective MAO Inhibitors



Antidepressants



Others




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7





FIGURE 8

Current desire to smoke


Comparison	F	p
Main effect of drug	8.220	0.003 **
Main effect of sex	2.190	0.170
Drug*sex interaction	3.390	0.054

Significant drug-vs-drug differences

	M 30	T 10
Plac	0.0007	0.0171
M 30		
T 10		



Baseline-adjusted mean of the post-drug cycles



Means are shown with standard errors



- Meth/Nic
- Plac/Nic
- Meth/Plac
- Plac/Plac

FIGURE 9

Carbon monoxide, parts/million

Comparison	F	p	Significant drug-vs-drug differences
Main effect of drug	3.880	0.022 *	Meth/Plac Plac/Nic Plac/Plac
Main effect of sex	0.380	0.554	Meth/Nic 0.0078 0.0082 0.0204
Drug*sex interaction	1.370	0.277	Meth/Plac Plac/Nic
Meth/Nic vs others	11.380	0.003 **	
Among others	0.100	0.904	

Increase during smoking



Legend: Meth/Nic (solid line, solid square), Meth/Plac (dashed line, open square), Plac/Nic (dotted line, solid circle), Plac/Plac (dash-dot line, open circle)

Means are shown with standard errors

FIGURE 10

Ratio of plasma nicotine increase to CO increase during smoking

Comparison	F	p
Main effect of drug	5.810	0.004 **
Main effect of sex	1.620	0.235
Drug*sex interaction	0.800	0.506
Meth/Nic vs others	16.720	0.000 **
Among others	0.380	0.689

Significant drug-vs-drug differences			
	Meth/Plac	Plac/Nic	Plac/Plac
Meth/Nic	0.0039	0.0061	0.0008
Meth/Plac			
Plac/Nic			




FIGURE 11

Number of cigarettes smoked

Comparison	F	P
Main effect of drug	3.670	0.026 *
Main effect of sex	0.470	0.509
Drug*sex interaction	1.480	0.243
Meth/Nic vs others	7.510	0.011 *
Among others	1.860	0.177





FIGURE 12




FIGURE 13

Number of grams of tobacco burned

Comparison	F	P
Main effect of drug	3.230	0.040 *
Main effect of sex	3.290	0.103
Drug*sex interaction	1.140	0.355
Meth/Nic vs others	8.930	0.006 **
Among others	0.380	0.687

Significant drug-vs-drug differences		
Meth/Nic	0.0262	
Meth/Plac		0.0079
Plac/Nic		





FIGURE 14

Latency between first two cigarettes, minutes

Comparison	F	p
Main effect of drug	2.820	0.060
Main effect of sex	0.810	0.392
Drug*sex interaction	0.170	0.914
Meth/Nic vs others	3.950	0.059
Among others	2.350	0.117

Significant drug-vs-drug differences		
	Meth/Plac	Plac/Nic
Meth/Nic		0.0097
Meth/Plac		0.047
Plac/Nic		



Means are shown with standard errors

FIGURE 15
Methoxsalen and Tranylcypromine Increase Oral
Nicotine Bioavailability and Decrease Desire to
Smoke





FIGURE 16

Extracts of St. John's Wort Inhibit Nicotine Metabolism in vitro





FIGURE 17

St. John's Wort (SJW) Increases Oral Nicotine Bioavailability in vivo




FIGURE 18

St. John's Wort (SJW) Increases Oral Nicotine Bioavailability in vivo






FIGURE 19




Estimated $K_i = 1 \mu\text{M}$
Calculated by PCS program $K_i = 1.1 \mu\text{M}$



Estimated $K_i = 2 \mu\text{M}$
Calculated by PCS program $K_i = 1.6 \mu\text{M}$

FIGURE 20



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- CA 9700506 [0006] [0024]
- WO 9534679 A [0007]
- RU 2066998 [0007]
- WO 9713489 A [0007]
- US 6006720 A [0021]
- US 60067021 B [0021]
- US 60084847 B [0021]
- US 60107392 B [0021]

Non-patent literature cited in the description

- **Lee et al.** Cigarette smoking, nicotine addiction, and its pharmacologic treatment. *Arch. Intern. Med.*, 1993, vol. 153 (1), 34-48 [0002]
- **Henningfield et al.** Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. *J. Pharmacol. Exp. Ther.*, 1985, vol. 234 (1), 1-12 [0003]
- **McMorrow MJ et al.** Nicotine's role in smoking: an analysis of nicotine regulation. *Psychological Bulletin*, 1983, vol. 93 (2), 302-27 [0003]
- Nicotine intake and its regulation by smokers. Tobacco smoking and nicotine. **Russell MSH ; Martin WR et al.** Advances, in behavioural biology. Plenum Press, 1987, vol. 31, 25-50 [0003]
- **Benowitz NL.** Drug Therapy. Pharmacologic Aspects of Cigarette Smoking and Nicotine Addiction. *New Engl. J. Med.*, 1988, vol. 319 (20), 1318-30 [0003]
- **Benowitz NL.** The Use of Biologic Fluid Samples in Assessing Tobacco Smoke Consumption. *NIDA Res. Monogr.*, 1983, vol. 48, 6-26 [0003]
- **Benowitz. NL et al.** Nicotine Metabolic Profile in Man: Comparison of Cigarette Smoking and Transdermal Nicotine. *J. Pharmacol. Exp. Ther.*, 1994, vol. 268 (1), 296-303 [0003]
- **Benowitz, NL et al.** Intravenous Nicotine Replacement Suppresses Nicotine Intake From Cigarette Smoking. *J. Pharmacol. Exp. Ther.*, 1990, vol. 254 (3), 1000-5 [0003]
- **Flammang et al.** Nicotine metabolism by cDNA-expressed human cytochrome P-450s. *Biochem. Arch.*, 1992, vol. 8, 1-8 [0005]
- **McCracken et al.** Cotinine formation by cDNA-expressed human cytochromes P450. *Med. Sci. Res.*, 1992, vol. 20, 877-878 [0005]
- **Yamano S et al.** The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. *Biochemistry*, 1990, vol. 29, 1322-1329 [0006]
- **Cholerton et al.** Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. *Journal of Chromatography*, 1992, vol. 575 (2), 325-30 [0006]
- **Rautio A et al.** Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. *Pharmacogenetics*, 1992, vol. 2 (5), 227-33 [0006]
- **Iscan et al.** Interindividual variability of coumarin 7-hydroxylation in a Turkish population. *Eur. J. Clin. Pharmacol.*, 1994, vol. 47 (4), 315-318 [0006]
- **Nakagina et al.** *J. Pharmazcol. Exp. Ther.*, 1996, vol. 272, 1010-1015 [0007]
- **Yamazaki et al.** *Carcinogenesis*, 1992, vol. 13 (10), 1789-1794 [0007]
- **Benowitz et al.** Stable isotope studies of nicotine kinetics and bioavailability. *Clin. Pharmacol. Ther.*, vol. 49 (3), 270-7 [0014]
- **Svensson.** Clinical pharmacokinetics of nicotine. *Clin. Pharmacokinet.*, 1987, vol. 12 (1), 30-40 [0014]
- **Zins et al.** Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. *J. Clin. Pharmacol.*, 1997, vol. 37 (5), 426-36 [0014]
- *Carcinogenesis*, 1990, vol. 11 (8), 1293-1300 [0027]
- **Yamazaki et al.** Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. *Carcinogenesis*, 1992, vol. 13 (10), 1789-94 [0027]
- **Fernandez-Salguero P et al.** A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. *Am. J. Hum. Genet.*, 1995, vol. 51 (3), 651-60 [0027]
- **Law et al.** The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. *Br. J. Cancer*, 1997, vol. 75 (11), 1690-1693 [0027]

- **Nunoya K et al.** A new deleted allele the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). *Pharmacogenetics*, 1998, vol. 8, 239-249 [0031]
- **Sambrook et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0033]
- **Staerz et al.** Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. *Proc. Natl. Acad. Sci. USA*, 1986, vol. 83 (5), 1453-7 [0065]
- **Staerz et al.** *Immunology Today*, 1986, vol. 7, 241 [0065]
- **Staerz et al.** Hybrid antibodies can target sites for an attack by T cells. *Nature*, 1985, vol. 314 (6012), 628-31 [0065]
- **Perez et al.** Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. *Nature*, 1985, vol. 316 (6026), 354-6 [0065]
- **Crespi CL et al.** A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. *Carcinogenesis*, 1991, vol. 12 (7), 1197-201 [0075]
- **Yun CH et al.** Purification and characterization of human liver microsomal cytochrome P-450 2A6. *Molec. Pharmacol.*, 1991, vol. 40 (5), 679-85 [0075]
- **Ding X et al.** Mossbauer studies on the metal-thiolate cluster formation in Fe(II)-metallothionein. *Eur. J Biochem.*, 1988, vol. 171 (3), 711-4 [0075]
- **Davies RL et al.** Development of a human cell line by selection and drug-metabolizing gene transfection with increased capacity to activate promutagens. *Carcinogenesis*, 1989, vol. 10, 865-891 [0075]
- **Heatherston et al.** The Fagerstrom Test for nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br. J. Addict.*, 1991, vol. 86 (9), 1119-1127 [0099]
- **Nemeth-Coslett R et al.** Nicotine gum: dose-related effects on cigarette smoking and subjective ratings. *Psychopharmacology*, 1987, vol. 92 (4), 424-30 [0170]